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Abstract 
This thesis describes the synthesis of enamino esters 3(S)-(.E)-benzoylamino-3-benzyl-
5-ethoxycarbonylmethylidene-1-methylpyrrolidin-2-one 77, and 3(S)-(E)-benzoylamino-
3-benzy 1-5-ethoxycarbony lmethy li dene-1-2, 4-dimethoxybenzy lamino-pyrrolidin-2-one 
79. These were designed as a new class of conformationally restricted amino acid 
analogue. 
Chapter one gives a general introduction to the importance of peptides in nature and 
the pivotal role peptides play in drug discovery and design. A number of examples are 
examined to provide an insight into key elements required in peptidomimetic design. 
Chapter two introduces the process of peptidomimetic design, in particular that of cis-
amide bond mimics. The synthesis of a new class of conformationally restricted 
peptidomimetic based on lactams is examined. 
Chapter 3 discusses the synthesis of succinic acid-derived, and aspartic acid-derived, 
~-keto esters and amides 23, 24, 28, via a Meldrum's acid procedure. This method 
provides the basis for the preparation of cyclic enamino esters. The preparation of the ~­
keto amide methyl-5-(N-ethoxycarbonylmethylcarbamoyl)-4-oxo-pentanoate 24 allowed 
chain extension in the C-direction in one easy step. 
Chapter 4 examines the importance of ene-lactams in nature and the synthesis of 
enamino esters 55, 56, 59, 61, and enamino amides 63 and 64,.via the reaction of a ~­
keto ester, or amide, with an amine. Compounds 59 and 61 represent examples of 3-
substituted cis-amide bond mimics that allow chain extension in both the N and C 
directions and subsequent incorporation into a peptide sequence. 
Chapter 5 describes the synthesis ofthe target phenylalanine-derived 3,3-disubstituted 
enamino esters 77 and 79, using the methodology established in chapter 4. Reaction of 
the enolate derived from (2R, 4S)-2-phenyl-3-benzoyl-4-benzyl-1,3-oxazolidin-5-one 65, 
with tert-butylbromoacetate gave (2R, 4S)-2-phenyl-3-benzoyl-4-benzyl-4-(tert-
butyloxycarbonylmethyl)-1,3-oxazolidin-5-one 67. An x-ray crystal structure of 67 
revealed that the reaction had proceeded with an inversion of configuration at C4, with 
the oxazolidinone ring being essentially planar in the solid state. This also revealed that 
6 
the stereochemistry at C3 could be determined by the stereochemistry of the amino acid 
from which it was derived. The tert-butyl ester was hydrolyzed and the resulting acid 
was converted to the ~-keto ester 71 upon reaction with meldrum's acid and EtOH. The 
~-keto ester (2R, 4S)-2-pheny 1-3 -benzoy 1-4-benzy 1-4-(3 -ethoxycarbony 1-2-oxopropy 1 )-
1 ,3-oxazolidin-5-one 71, was reacted with either methylamine, or 2,4-
dimethoxybenzylamine (DMBNH2), and heated at 150° C, under reduced pressure, to 
give the target 3,3-disubstituted enamino esters 77 and 79. The target enamino ester 77 
and 79 allow chain extension in both the N and C-directions and are designed to be 
incorporated into a peptide sequence to mimic a cis-amide bond and allow investigation 
into the bio-active conformation of a specific peptide. 
ACE 
AIDS 
Cbz or (Z) 
Abbreviations 
angiotensin converting enzyme 
acquired immune deficiency syndrome 
benxyloxycarbonyl 
0 
()0~ 
DMB 2,4-dimethoxybenzyl 
~ 
n MeO ~ OMe 
DMF N ,N -dimethyformamide 
GH growth hormone 
GSH glutathione 
HIV human immunodeficiency virus 
IC5o concentration required to inhibit cell growth by 50% 
NOE nuclear overhauser effect 
PTH parathyroid hormone 
TF A trifluoroacetic acid 
THF teirahydrofuran 
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Peptides and proteins are the indispensable agents of biological function and as such 
they are essential components of all organisms. In addition to their bio-catalytic 
functions, in the form of enzymes, proteins are also important components of tissues. 
Peptides play a vital role within an organism acting as chemical regulators and 
messengers. Numerous examples of biologically active peptides have been identified 
and characterized in recent decades. Biologically active peptides have been found to act 
as neurotransmitters, neuromodulators and hormones. Peptides have further been 
identified as pivotal components in the regulation of physiological processes within an 
organism. By interaction with a specific receptor, these peptides control a series of vital 
functions such as metabolism, cell-cell communication, digestion, immune response, 
respiration, sensitivity to pain, reproduction, behaviour and electrolyte levels. It is 
therefore of no surprise that biologically active peptides are of enormous interest to 
medicine and medicinal chemists. Medical conditions including hypertension, 
emphysema, gatrointestinal diseases, diabetes, Acquired Immune Deficiency Syndrome 
(AIDS), neuropsychiatric disorders, fertility disorders, prostate cancer, pain and 
inflammation can be treated with therapeutic agents which imitate, or block, the function 
of biologically active peptides and their receptors or enzymes. 
This introduction will give a brief overview of the structure and properties of 
biologically important peptides, along with a number of examples illustrating their 
importance in human biology. Finally, the role of peptides in the process of drug 
discovery and design will be addressed, with a particular emphasis placed on their use in 
the development of natural product-based systems and peptidomimetics. 
Biologically Active Peptides 
Advances in chemistry, medicine and molecular biology have allowed the 
identification and characterization of many biologically active peptides and proteins 
found in nature. Peptides play an essential role in human biology in such processes as 
nerve stimulation and biochemical regulation (e.g. hormones). Due to their exceptional 
specificity, such peptides are not recognized by incompatible receptors, and the level 
needed to induce a response can remain relatively low. What follows is an account of a 
Chapter 1 Introduction 10 
number of important biologically active peptides that have been shown to play vital roles 
in human biological function. 
Glutathione 
Glutathione (L-y-glutamyl-L-cysteineglycine or GSH) is widely distributed in nature 
and occurs in virtually all animal cells, often in relatively high concentrations (0.1 - 10 
mM). 1 This simple tripeptide is the most abundant intracellular thiol in almost all 
aerobic biological species due to the relative stability of its y-peptide bond to 
degradation by protease enzymes. GSH has evolved as a molecule that provides 
protection against oxidation2 and as such it has a number of important functions in 
metabolism, catalysis and transport. As an antioxidant its function is closely associated 
with the maintenance of a reductive environment in the interior of a cell. GSH 
maintains enzymes and other cellular components in a reduced state, while also 
protecting the cell against damaging radical and non-radical products of oxygen. 
Glutathione was first observed as a reducing agent in yeast as early as 1888, but it was 
not until1921 that F. G~ Hopkin carried out a successful isolation. Its formulation as an 
y-peptide of glutamic acid, cysteine and glycine was made by Pirie and Pinhey in 1929. 
Insulin 
I I 
G ly-Ile V al-G lu-G ln-Cys-Cys-Thr-Ser-lle-Cys-Ser-Leu-Tyr-Gin-Leu-G lu-Asn-Tyr-Cys-Asn 
Phe-Val-Asn-G ln-His-Leu-~s-G ly-Ser-His-Leu-Val-G lu-Ala-Leu-Tyr-Leu-Val-Cts-G ly-G lu-Arg-G ly-Phe-
Phe-Tyr-Thr-Pro-Lys-Thr 
Insulin3 is the primary peptide responsible for the regulation of glucose metabolism. It 
is produced by the so-called Langerhans islet cells in the pancreas, where it is released to 
act on nearby liver cells to regulate the breakdown of glycogen to glucose. A deficiency 
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of insulin leads to increased blood glucose levels and the common deficiency disease 
diabetes millitus. 
While diabetes still remains the third leading cause of death in the US today (a serious 
health risk) treatment of patients is possible through the industrial synthesis of human 
insulin via microbial fermentation. 4 This process involves the incorporation of the 
appropriate DNA sequence into a cell's nucleus with the resulting expressed peptide 
being isolated for clinical use. This powerful technique utilizes the cells own protein 
synthesizing ability to synthesize a peptide surplus to its needs. Insulin was first isolated 
in 1922 by Frederick G. Banting and Charles H. Best and consists of two peptide strands 
linked by disulphide bridges to give a complex three-dimensional structure. 
Oxytocin and Vasopressin 
I I C)ts-Tyr-Ile-Gln -Asn-C)ts -Pro-Leu-Gly-NH2 Oxytocin 
I I 
cys-Tyr-Phe-Gln-Asn-C)ts-Pro-Arg-Gly-NH2 Vasopressin 
The peptide hormones5 oxytocin and vasopressin originate in the pituitary gland, or 
neurohypophysis, an important regulatory gland at the base of the brain. Both are 
relatively small polypeptides with strikingly similar structures (where oxytocin has 
leucine and isoleucine, vasopressin has arginine and phenylalanine). Despite the 
similarity of the two amino acid sequences, these two polypeptides have quite different 
physiological roles. 
Oxytocin is found only in females and stimulates uterine contractions during childbirth 
and the release of milk from the mammary gland during child rearing. 
Vasopressin occurs in both males and females and causes contractions of peripheral 
blood vessels, and hence an increase in blood pressure. Its major function, however, is 
as an antidiuretic (induces water retention in the kidneys) and is often referred to as an 
antidiuretic hormone. 
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The structure of oxytocin and vasopressin also illustrates the importance of disulphide 
linkages between cysteine residues in maintaining the overall structure of a polypeptide. 
In these two molecules the disulphide linkages lead to a cyclic structure. 
Although the physiological effects of these peptides were first observed, by H. H. 
Dale, as early as 1906, it was not until 1953 that the structure of oxytocin was 
determined by du Vigneaud, Ressler and Trippit. The structure of vasopressin soon 
followed with efforts in these areas leading to great advances in peptide synthesis and 
elucidation. Vincent du Vigneaud was later awarded the Nobel prize for his role in this 
work.6 
Renin-Angiotensin System 
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe 
1 
The Renin-Angiotensin system plays an important role in the regulation of blood 
pressure? Increases in instances of cardiovascular diseases, such as hypertension and 
heart failure, have been attributed to an imbalance in this system. The system involves 
two enzymes, Renin and Angiotensin Converting Enzyme (ACE), which catalyze the 
release of angiotensin (1), one of the most potent known vasoconstrictors. This process 
begins in the liver with the synthesis of the large 60kD protein angiotensinogin. This 
peptide is then passed into the blood stream and is transported to the kidneys where it is 
cleaved by an aspartic acid protease (Renin) to give Angiotensin I. Angiotensin I is then 
further cleaved by ACE, primarily in the lungs, to give the biologically active 
octapeptide Angiotensin II (1). Upon binding to specific receptors on the surface of 
cells, 1 affects blood pressure directly by constriction of blood vessels, and indirectly by 
the release of the hormone aldosterone, from the adrenal gland, to induce sodium ion 
and water retention. Inactivation of 1 occurs by enzymatic cleavage of the C-terminal 
residue to give Angiotensin III. 
Successful antihypertensive drugs such as Captopril8 are used in medicine to mediate 
such cardiovascular disorders. Captopril, like other hypertensive agents, inhibits the 
~C~h~a~p~te~r~l~In~t~r~o~d~u~c~ti~o~n--------------------------------------------~13 
action of ACE on its substrate angiotensin I. Determination of the amino acid sequence 
of the biologically active peptide Angiotensin II occurred in 1956. 
Calcitonin and Parathyroid Hormone 
I I H-Cjs-Gy-Asn-Leu-ser-Thr-Cjs-Met-Leu-Giy-Tirr-Tyr-Thr-GI.n-Asp-Phe-
Asn-Lys-Phe-His-Thr-Phe-Pro-Gin-Thr-Ala-lle-Gly-Val-Gly-AlaPro-NH2 
calcitonin 
Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-
Leu-Arg-L ys-Lys-Leu -Gln-Asp-Val-His-Asn-Phe-Val-Ala-Leu-Gly-Ala-Pro-Leu-Ala -Pro-Arg-Asp-Ala-
Gly-er-Gln-Arg-Pro-Arg-Lys-Lys-Glu-Asp-Asn-Val-Leu-Val-Gln -Ser-His-Glu-Lys-Ser-Leu-Gl y-Glu-
Ala-Asp-Lys-Ala-Asp-Val-Asp-Val-Leu-Thr-Lys-Ala-Lys-Ser-Gln 
hmnan parathyroid hormone (PTHh) 
The vital regulation of the level of calcium ions in the blood is under the control of 
two peptide hormones. The parathyroid hormone (PTH) raises the concentration of 
blood calcium by mobilizing calcium uptake from the bones, while the thyroid hormone 
calcitonin directs the flow of calcium ions in the opposite direction. Thus a constant 
balance of calcium ion level is maintained in the blood. 
The discovery of calcitonin9 in 1962 by D. H. Copp led to it becoming a major focus 
of investigation in medicine. It was hoped that it would be of value in the treatment of 
osteoporosis and other diseases associated with the loss of calcium from the bones. Of 
the calcitonin isolated from various species, the hormone from salmon shows 
exceptionally high activity and is therefore used for therapy. However, the human 
hormone, despite its lower activity, is often preferable as it avoids the concerns of 
antibody formation. The complete sequence of the human parathyroid hormone10 was 
obtained in 1978 and found to be a chain consisting of 84 amino acid residues. 
Somatistatin 
Ala-Gy-Cys-Lys-Asn-Phe-Phe-Trp 
~ I HO-cys-ser-Thr-Phe-Thr-Lys 
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Somatistatin, first isolated and characterized in 1973,11 is a 14-residue cyclic peptide 
synthesized in the hypothalamus. Its biological function is as a release-inhibiting 
hormone, preventing the release of growth hormone (GH) from the pituitary gland. It 
also inhibits the secretion of several other hormones including those acting on the 
pancreas to prevent the release of insulin and glucagon. A lowered level of glucagon is 
beneficial in certain types of diabetes millitus, therefore somatistatin became an 
important target in medical research. 
Somatistatin has been implicated in a vast array of actions in the central and peripheral 
nervous systems as well as in autocrine and paracrine regulation. As such it has been 
shown to have multiple receptor sites with five human somatistatin receptor sites having 
been identified. 12 Identification of these receptor sites has led to therapeutic uses of 
somatistatin, and its analogues, in the treatment of gastric ulcers, acromegalia, carcinoid 
tumours and intestinal sclorodoma. 
Properties of Amino Acids and Peptides 
Chemically, peptides and proteins (there is no clear distinction between the two) 
consist of linear sequences of amino acid building blocks joined by an amide linkage 
called a peptide bond. Two or more linked amino acids are called a peptide, while· a 
long polypeptide chain is usually referred to as a protein. Although there are many 
hundreds of amino acids found in nature, there remains an exclusive group of only 
twenty primary amino acids of which nearly all peptides and proteins are made. Even 
with this seemingly small group of building blocks, the scope for diversity within any 
one peptide sequence is still quite staggering. For example, a simple tetrapeptide 
sequence offers over 200,000 possible combinations. Mammals e.g. humans, can only 
synthesize ten of the twenty primary amino acids. Those that can be synthesized in the 
body are classified as non-essential; that is, they are not required to be part of the diet. 
In contrast, those amino acids that cannot be synthesized are classified as essential and 
must be obtained from dietary sources, in particular the digestion of plant material. 
Plants synthesize amino acids by way of nitrogen fixation and the reduction of nitrates 
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from the soil to give ammonia. This is then incorporated into a number of biosynthetic 
pathways to produce the various amino acids required for metabolism. 
The general structure of a primary amino acid consists of an amino group (NH2), a 
carboxylic acid (COOH) and a side chain group R attached to a central carbon atom 
(Ca)· The primary amino acids differ only in the nature of the R group and it is the 
interactions between these groups within a peptide sequence that gives· rise to the unique 
chemical and biological characteristics of that sequence. Of the two possible 
enantiomers, only that designated as the L-enantiomer is found in most peptides and 
proteins. 
R}I 
H2N-¥nOH 
0 
A primary L-amino acid 
The formation of a peptide bond between two amino acids involves the formation of a 
covalent bond between the carbonyl group of one amino acid and the amino group of 
another. 
+ 
Formation of a peptide bond 
H ~ e 
N c-c02 
H 
The peptide backbone of a peptide or protein consists of the repeated sequence -N-Ca-
CO-, where the N is the amide nitrogen, Ca the a-carbon of the amino acid in the 
polymer, and the final Cis the carbonyl carbon of the amino acid, which is in turn linked 
to the next amino acid in the chain. The geometry of the peptide bond is shown below. 
Note that the carbonyl oxygen and the amide hydrogen have been drawn trans. This 
conformation is favoured thermodynamically as it results. in less steric hinderance 
between the R groups of adjacent amino acids. However as we shall see in later 
examples, it is the manipulation of this conformation (and in many cases manipulation 
towards the cis configuration) that gives rise to biological activity. 
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Peptide bond geometry 
One important property of a peptide bond is its ability to display partial double bond 
character. Two resonance structures can be shown to exist for a peptide bond. A pure 
double bond (a) between C and 0 would permit free rotation about the C-N bond, while 
the other resonance structure (b) would prohibit C-N bond rotation, but would place too 
great a charge on 0 and N. The true electron density (c) lies somewhere in between. 
The barrier to C-N bond rotation of, about 88kJ/mol, is enough to keep the amide group 
planar. 
Ca H 
F~ eo Ca 
(a) (c) (b) 
An essentially planar amide bond has a number of consequences, includimg placing all 
six atoms in a peptide bond group in the same plane. This creates a type of link effect 
with the principle point of rotation being about the a-carbon. 
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Peptide 'link' effect. 
The typical charge separation in an amide bonds means that the peptide backbone is 
quite polar, and hence is suitable for hydrogen bonding between the positively charged 
hydrogen on the nitrogen and the negatively charged carbonyl oxygen. 
-0.39 
0 
+~ / 
N-o.28 
I 
H 
+0.28 
This type of interaction leads to a folding and coiling of the peptide chains, in an 
ordered way, to give secondary and tertiary structure. Three-dimensional structures 
such as the a-helix and P-pleated sheet result and these occur regularly throughout 
proteins and form the basis of overall protein structure. 13 
(b) (a) (c) 
(Diagram of pancreatic trypsin inhibitor showing (a) secondary and tertiary structure: 
(b) a-helix, (c) P-pleated sheet.) 
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As virtually every cellular activity is dependent on one or more particular proteins, the 
relationship between the three-dimensional structure, and the resulting function of a 
protein, has been an area of intense study for many years. 14 
A convenient way to classify the enormous number of proteins is by the biological 
function they fill. Table 1 below summarizes the classification of proteins by function 
and gives a few representative examples of each class. 
Table 1 Biological Functions of Proteins and Some Representative Examples 
Class Example Function 
Enzymes -Chymotrypsin -catalyzes hydrolysis of dietary proteins 
-Catalase -catalyzes hydrolysis ofRNA 
-HIV -catalyzes processing of AIDS virus proteins 
Regulatory -Insulin -regulates glucose metabolism 
-lac repressor -inhibits enzyme system responsible for lactose 
metabolism 
-CAP -increases transcription rate of adjacent 
genes in E. coli chromosomes 
Transport -Hemoglobin -transports oxygen from lungs to tissue 
-Glucose transporter -transports glucose across cell membrane 
Storage -Casein -most abundant milk protein, major source 
of nitrogen for mammalian infants 
-Ferritin -iron binding protein used to store iron for 
use in important iron containing proteins 
ie hemoglobin 
Contractile/ -Tubulin -major component of microtubules 
Motile (involved in cell division) 
-Dynein, Kinesin -propel intracellular movement of vesicles, 
granules and organelles 
Structural -a-kerratin -insoluble fibrous protein making up hair, 
horns and fingernails 
-Collagen -strong fibrous protein found in bone, 
connective tissue, tendons and cartilage 
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-Elastin -important component of ligament 
-Fibroin (~-keratin) -major component of cocoons (silk) and 
spider webs 
Protective -Immunoglobin -immune response involved in fighting off 
(antibodies) infection 
-Thrombin, -blood clotting proteins 
Fibrinogen 
-Ricin -plant toxin to thwart consumption 
Exotic -Antifreeze proteins -present in Arctic/ Antarctic fish to prevent 
their blood from freezing 
-Resilin -elastic protein found in the hinges of 
insect wings 
-Glue proteins -present in some marine organism to allow 
attachment to hard surfaces 
It is worth repeating at this point that the great diversity of function in proteins, as 
reflected in the above table, is obtained using just twenty amino acids. 
Protease Enzymes 
An important class of proteins, are those classified as protease enzymes. Protease 
enzymes constitute a large family of enzymes, which catalyze the hydrolysis of amide 
linkages in proteins and polypeptides. These enzymes are active in the digestion of 
food, the release of peptide hormones and neuromodulators from inactive precursors, 
activation of enzymes, and termination of biological responses by the degradation of the 
message transmitting peptide. Four classes of protease enzyme15 have been identified, 
each with a characteristic mechanism of catalysis. These are classified as serine, 
aspartic, cysteine or metallo proteases based on the most significant catalytic functional 
group present in the enzyme active site. Illustrated below, in Table 2, are some 
examples of each of the classes of protease along with their associated biological 
function. In many medical conditions it is the inhibition of these enzymes that forms the 
basis for overall treatment. 
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Table 2 Examples ofProteases, Subdivided into Mechanistic Catagories 
Protease Significant Active Example Function 
Site Groups 
Serine Ser (hydroxyl) chymotrypsin, trypsin, digestion 
His (imidazole) pancreatic elastase 
Asp (carboxyl) 
thrombin, plasma kallikrein, blood coagulation 
factors VIla, IX-Xlla, 
activated protein C 
tissue kallikrein, post hormone 
protein cleaving metabolism 
enzyme 
elastase, cathepsin G, most phagocytosis 
cell chymases, tryptases 
ATP dependent proteases protein turnover 
Metallo Zinc angiotensin converting blood pressure 
enzyme (ACE), amino- regulation 
peptidases, renal dipeptidases 
carboxypeptidase digestion 
collagenase tissue elasticity 
macrophage elastase blood pressure 
regulation, peptide 
metabolism 
Aspartic Asp (carboxyl) renm blood pressure 
regulation 
HIV protease HIV replication 
pepsin, thermolysin digestion 
Cysteine Cys (thiol) cathepsins B, H, L, calcium protein turnover, 
activated neutral proteases bone resorption 
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Peptidomimetics 
Peptides and their analogues have long been used in medicinal chemistry as 
therapeutic agents against a range of pathological conditions, generally characterized by 
a disruption of the interactions between an enzyme substrate or messenger and their 
targets, the enzymes and receptors. The use of biologically active peptides as 
therapeutic agents is often severely limited by their pharmacological properties. In 
particular, degradation in the gut and serum, poor absorption after oral ingestion and 
rapid excretion through the liver and kidneys restrict their usefulness as drugs. In 
overcoming these problems there has been an increasing tendency towards the use of so 
called chemical 'Trojan horses' or peptidomimetics. 16 
"A peptidomimetic is defined as a substance having a secondary structure as well as 
other structural features analogous to that of the original peptide that allow it to displace 
the original peptide from its receptor or enzyme. As a result, the effects of the original 
peptide are either inhibited (antagonist, inhibitor) or duplicated (agonist)."16 
A successful peptidomimetic, while possessing all these characteristics, must also be 
sufficiently non-peptidic to overcome the problems of degradation and bio-availability 
associated with peptides, while exhibiting minimal side effects. This has led to the 
development of new and more effective types of treatment for a wide range of diseases. 
There are two sources of peptidomimetics: natural sources, and rational drug design 
and synthesis. Natural products have long served as a significant source of important 
peptidomimetics. Screening of extracts for a particular biological activity from plant, 
animal, microbial or fungal sources provide an invaluable guide to the identification and 
isolation of bio-active natural products. In this way important leads in drug discovery 
and development can be revealed for the potential treatment of specific diseases. This is 
often achieved through mass screening and relies on tl;le assumption that a desired active 
compound already exists in nature. Examples of successful natural product 
petidomimetics include Cyclosporin A (CsA), FK-506 and ro-conotoxin MviiA. 
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FK506 
~e H' 
0 
Q 
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CsA17 and FK-50617 are generally viewed as immunosuppressants, with the 
macrocyclic peptide CsA having emerged as the principle immunosuppressive agent for 
solid organ transplants. The wealth of studies surrounding the interactions of CsA, and 
the macrolide FK-506, with their corresponding immunophilin receptors have greatly 
advanced research in immunosuppressants. 
l 
CKGKGACSRLMYCCTGSCRSGC 
disulphide bonds 
co-Conotoxin MviiA 
N 
The marine natural product co-conotoxin MviiA18 is currently in Phase II/III clinical 
trials as a powerful agent against intractable pain. It has high selectivity for N-type Ca2+ 
channels and with the added characteristic of being non-addictive, is touted as the future 
alternative to morphine. Other novel bio-active peptides, particularly of marine origin, 
continue to be isolated and promise to assist in the design of new therapeutic agents. 
Alternatively, a peptidornimetic may be obtained through the process of rational 
design and synthesis. This involves obtaining a detailed knowledge of the 
conformational, topochemical and electronic properties of the native peptide and that of 
its corresponding receptor or enzyme active site. 
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The design of peptidomimetics as potential bio-active substances must take particular 
account of two structural factors. 16 
1) Favourable fit - this involves identifying the bio-active conformation(s) 
corresponding to the complementary spatial situation at the receptor or active site. If 
necessary, the conformation of the peptidomimetic can be stabilized by the introduction 
of elements conferring rigidity. 
2) Favourable interactions- this involves the placement of certain functional elements 
(e.g. functional groups, polar and hydrophobic regions) in defined positions so that the 
required interactions (e.g. hydrogen bonds, electrostatic or hydrophobic interactions) can 
occur. 
Structural Possibilities in Peptidomimetic Design 
From a structural point of view, peptidomimetics can be prepared by approaches 
ranging from the slight modification of the initial structure to the generation of a pure 
non-peptide. These approaches are categorized below. 
Modification of the Side Chains of Amino Acid Residues 
The incorporation of unnatural amino acids and amino acid surrogates into peptides by 
chemical methods has often been used to study structure-function relationships. The 
replacement of a residue by its optical isomer provides useful information regarding 
possible turn sites while modification of a side chain gives clues to its role in the bio-
active conformation. 
A recent example demonstrates that this is still important today. Modification of the 
tyrosine side chain, by the introduction of methyl groups at the 2', 6' and P-positions/9 
hinders free rotation about the Ca.-C 13 bond and can thus favour the formation of bio-
active conformations. This has been used to study the effects of restricted rotation of 
aromatic side chains in the interior of proteins20 (e.g. bovine pancreatic trypsin 
inhibitor),21 as well as peptide-protein complexes (e.g. oxytocin and neurophysin) 19 and 
bio-active peptides (e.g. methionine-enkaphilin). 19 
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Modification of the Peptide Backbone 
Modification of a peptide backbone generally involves the exchange of units within a 
peptide chain with electronically and/or sterically equivalent units, as well as the 
incorporation of additional units. This generally leads to an increase in the biological 
half-life in comparison to the native peptide. 
A common approach is the replacement of an amide bond with a suitable mimic. This 
has proved important in the development of enzyme inhibitors as it can result in a 
compound resistant to hydrolysis. Cases where amide bonds have been replaced with a 
ketoethylene (COCH2) or a hydroxyethylene (CH(OH)CH2) have led to compounds that 
are among the most active inhibitors of Renin and HIV -1 protease. Some common 
examples of peptide backbone modifications are outlined below. 16 
Replacement of: Fragment addition: 
-NH- -CH(R)- -CO- -CO-NH- -NH-X-CH(R)-
-0- -N- -CS- -NH-CO- -0-
-S- -CR- -CH2- -CH(OH)-CH2- -NH-
-CH2- -BH- -S02- -CH=CH- -CH2-
The development of the therapeutic agent Captoprif2 (see earlier) is a simple and yet 
prime example of enzyme inhibition by modification of a peptide backbone. Captopril 
prevents the release of the hypertensive peptide hormone Angiotensin II by inhibiting 
the enzyme responsible for its production - Angiotensin Converting Enzyme (ACE). 
Lowering the Angiotensin II levels reduces chronic high blood pressure and thus the 
incidents of heart failure and strokes. Captopril was developed from the lead structure 
(2), a simple dipeptide shown to be a weak inhibitor of ACE. Replacemeq~ ~f the 
terminal amine of (3) with a mercapto group gave the potent and orally active drug 
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Captopril. 16'23 The mercapto group was introduced to coordinate to a zinc ion which is 
known to be located in the active site of ACE. 
1 Asp-Arg-Val-Try-Ile-His-Pro-Phe 
Inducement and Stabilisation of Secondary Structure (p-turns, y-turns, a-helix, P-sheet) 
Secondary peptide structure plays an important role in biological activity. a-Helices, 
~-sheet structures, turns and loops are all essential components of peptides and 
proteins. 13' 14 Therefore, the retention of such structures by mimeticism is an important 
tool for the fixing of the bio-active conformation in a peptide containing these elements. 
A good example of this is the ~-turn, an element widely recognized as being important 
as a molecular recognition site. A common ~-turn consists of 4 amino acids and is 
stabilized by a hydrogen bond between the carbonyl of the first and the NH group of the 
fourth. The main feature of a ~-turn is the reversal of the peptide chain by 
approximately 180°. 
Compounds 4,5 and 6 are examples of ~-turn mimics and demonstrate that the 
structural motifs involved can range from still recognizable peptide chains to completely 
non-peptidic components. 
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Scaffold Peptidomimetics 
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This class of peptidomimetics utilizes a completely unnatural framework to support 
the elements of the original peptide responsible for its effectiveness. Compounds of this 
type appear particularly interesting with regards to their potential oral bio-availability. It 
is therefore possible to use frameworks or structural elements of known compounds 
whose oral absorption properties are established. 
A successful example of this technique involved the macrocyclic hormone 
Somatistatin?7 Extensive structure-function and conformational studies led to the 
discovery of a non-peptidyl partial somatistatin agonist 7, containing a ~-D-glucose 
scaffold?8 Another example 8, utilizes a cyclic urea scaffold and has been shown to be 
a potent in vitro inhibitor of HIV-I protease?9 These examples demonstrate the ability 
of scaffolds to hold key functional elements in the desired bio-active conformation. 
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Non-Peptide Mimetics 
Non-peptide mimics have generally been discovered through the course of random 
screening of large numbers of substances, including microbial extracts and fungal 
metabolites. These mimetics belong to various classes of organic compounds and bare 
no apparent structural resemblance to the native peptide. Once a bio-active structure has 
been obtained, attempts can be made to optimise its structure through systematic 
structure modification. The analgesic morphine 9 is an example of a completely non-
peptide mimetic, while compound 10 has arisen through development of antagonists of 
the pituitary hormone oxytosin. It has shown to be a potent antagonist with an ICso 
value ofless than 10 nM.30 
9 10 
Conformation Stabilizing Rings 
The final, and perhaps the most important class of peptidomimetics, in terms of this 
thesis, is that of· conformational stabilizing rings. This has proven to be a successful 
method for the development of peptidomimetics and involves the introduction of bridges 
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of varying lengths between different parts of the molecule, thereby making the molecule 
more rigid. With careful design, this has the effect of imitating the receptor bound 
conformation of the biologically active peptide and thus allows investigation into the 
relationship between peptide structure and function. 
In the past most enzyme inhibitors have been based on either substrate analogues or 
transition state mimics. However, these inhibitors have been hampered by poor stability, 
bio-selectivity and bio-availability. The introduction of conformational restriction into a 
drug can improve potency by locking it in a bio-active state and reducing the loss of 
entropy that occurs upon its binding to a receptor or enzyme active site. This increased 
potency may in turn permit the use of fewer amino acid residues in a peptide recognition 
sequence, thereby lowering the molecular weight and improving bio-availabilty. 
The specificity of the inhibitor for an enzyme may also be enhanced by excluding 
conformations that are capable of inhibiting other enzymes. Commonly, two adjacent 
amino acid residues are involved in bridging but there are many other sites where this is · 
possible. These include within a single amino acid (11), between two amino acid side-
chains (12), between backbone units (13) or between a backbone unit and a side chain as 
in the case of (14), a potent inhibitor of ACE. 
R' 
1\ ~ , 
--N N_/ I( K o 
R 0 
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Compounds 15 and 16 are examples ofmacrocyclic peptidomimetics where the P, and 
P3 residues are linked to bring them close in space and induce biological activity. Both 
15 and 16 and their derivatives are potent inhibitors (1-30 nM) of HIV protease and 
display enhanced metabolic stability relative to acyclic inhibitors. 
Ag-:p 
Ile-Val-NH2 
Research Described in this Thesis 
This thesis is concerned with the synthesis of a new class of conformationally 
restricted amino acid analogue, as a potential tool in enzymatic studies. The proposed 
system is based on a lactam. The target molecules are illustrated in Figure 1, alongside 
the analogous section of peptide backbone they are intended to mimic. 
ZHN 
R"h 0 o~NA-lloEt 
X 
Peptide Sequence 
Target Molecule 
X=Me,DMB 
DMB=2,4-dimethoxybenzyl 
Figure 1 Target cis-amide bond mimics 
The target peptidomimetics bridge the peptide backbone as shown. This restricts the 
otherwise free rotating system about the amide bond (indicated by \jf). The result is to 
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lock the peptide bond in a cis-like conformation* which, in many cases, is known to be 
biologically important. Although this does not necessarily lead to an enzyme inhibitor, 
by studying the change in enzyme activity, information can be obtained concerning the 
preferred conformation of natural substrates. These results would provide valuable 
insights into the optimal conformation required for biological function. 
* This assignment adopts the standard method practiced in peptide chemistry, whereby 
the configuration of the peptide backbone is said to be cis and does not recognize the 
higher priority of the carbonyl oxygen relative to the CN bond.37 
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An important principle in the design and synthesis of peptidomimetics is 
conformational restriction (refer to Introduction). This involves the flexibility of a 
system being restricted in some way to promote biologically active conformations. By 
replacing one or more components of a target peptide with various structural 
modifications, thereby restricting the degree of rotational freedom along the peptide 
backbone, it is possible to probe the conformational requirements of the peptide for 
biological activity. 
Modifications of this type have also been shown to improve the pharmacological 
properties of such analogues by reducing their peptidic character. This can lead to an 
increase in bio-stability and hence compounds more suitable for therapeutic use. The 
aim of this process is to produce a non-peptidic ligand constrained to adopt the 
appropriate bio-active conformation. 
Freidinger lactams 
Conformational restriction of a peptide chain can be achieved in a number of ways. 
Perhaps the most successful and widely used strategy is that of cyclization. This 
involves the introduction of bridges of varying lengths between different parts of the 
molecule, thereby making the molecule more rigid. Among this most important class of 
compounds, Freidinger lactams, and their close relatives, have proved among the most 
useful in drug design. 
A Freidinger lactam is derived from a peptide in which the a-position of an arbitrarily 
chosen amino acid residue has been connected to a down-stream amide nitrogen through 
the addition of a carbon bridge. The original Freidinger lactam,38 and the motif most 
commonly used, involves the formation of a ring from the position normally occupied 
by the i, side-chain forming a 3-amino (or 3-amido) lactam (see Figure 2). 
Alternatively, it is possible to replace the a-hydrogen of this residue with the bridging 
ring while still retaining the normal side-chain. Peptidomimetics in which the nitrogens 
of adjacent residues are linked have also been reported (see Figure 2).33 
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Figure 2 Freidinger lactams derived from a peptide 
Freidinger and his colleagues at Merck ftrst reported the use of Ca-N cyclizations for 
the constraint of peptides in 1980.38 By far the most influential paper published in this 
fteld concerned their design and synthesis of a potent analogue of the hypothalamic 
hormone luteinizing-hormone-releasing hormone (LHRH, also known as gonadotropin-
releasing hormone GRH). This analogue contained a lactam constituent, that 
successfully constrained the peptide to imitate the Tyr-Gly-Leu-Arg type II ~-tum in the 
bio-active conformation of the molecule (Figure 3). This lactam-containing analogue 
was found to be 8.9 times more potent as LHRH in an in vitro pituitary cell culture study 
and 2.4 times as potent in an in vivo rat study. 
pyroGlu-His-Trp-ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
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Figure 3 Incorporation of a lactam constituent to mimic ~-tum ofLHRH 
Further investigations of the uses of these lactams for several other biological targets 
revealed them to be a successful general tool in achieving conformational constraint of 
bio-active peptides. 
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The most in-depth use ofFreidinger lactams has been for the control of blood pressure, 
by interfering with the Renin-Angiotensin system (see introduction). The incorporation 
of 17 into inhibitors of Renin, led to more potent inhibitors which were resistant to 
degradation by chymotrypsin. For example 18 was shown to have an IC50 of 1.3 nM, 
whereas the corresponding analogue, where the lactam ring was removed, had an IC50 of 
45 nM, a 35 fold reduction in potency?9 
(lo 
Bo~ly~-r~ 
0 - OH 0 rNH 
N.::::::::! 
17 18 
Attempts to follow up the enormous commercial success of the Angiotensin 
Converting Enzyme (ACE) inhibitor Captopril 3 (see Introduction), and enalapril, led to 
new classes of inhibitors containing the lactam substituent being developed for the 
treatment of hypertension and congestive heart failure. Studies of five-, six-, seven-, and 
eight-member lactams as conformationally restricted analogues of enalaprilat, an ACE 
inhibitor, led to the determination of \jJ (the torsion angle) in the bio-active conformation 
of enalaprilat. 40 This information was then used to develop enalaprilat analogues of 
increased potency, such as cilazaprilat, constrained to the optimum \jJ angle. 41 
PhJ~nN? 
'V 0 C02H 
enalapril (R=Et) 
enalaprilat (R=H) 
II cyclization, D, ring removal 
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Ph~II~N 
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The use of Freidinger lactams to incorporate latent reactivity has also been used in the 
development of mechanism-based inhibitors of the serine protease chymotrypsin. 
Compounds of type 19,42 which include a substituted lactam ring, can lead to the 
covalent binding of the inhibitor to the enzyme active site (Figure 4). 
Enz 
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Figure 4 Freidinger lactams as Mechanism-based Inhibitors of Serine Proteases 
cis-Amide bond mimics 
It is worth pointing out at this stage that all the examples of Freidinger lactams 
discussed to date, place the amide bond within the lactam ring and constrain it to a trans 
configuration, with respect to the peptide backbone. This, it would seem, has been the 
focus of applications of Freidinger lactam and has proved successful in the development 
of peptidomimetics for processes where this is a desired bio-active conformation. 
However, the partial double bond character of an amide bond leads to cis and trans 
isomers. As was discussed earlier (see Introduction), the configuration of an amide bond 
in a peptide is of crucial importance to the overall conformation of the molecule, and 
therefore to its ability to bind to a receptor. In many cases, binding to a receptor will 
only occur with a cis-configuration at certain amide bonds. 
In nature, cis-amide bonds can occur in the form of N-alkylated amides, secondary 
structures such as turns, constrained cyclic peptides and bio-active conformations. In a 
normal amide bond, the trans configuration is thermodynamically favoured over the cis 
by approximately 10 kcal/mol, due to less steric hinderance between adjacent groups. In 
N-alkylated amides, for example, the energy difference between the cis and trans 
isomers is only about 2 kcal/mol, due to both isomers having similar 1,4-interactions, 
and the cis and trans forms can both be observed by NMR spectroscopy. N-Alkylated 
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ami des are found in a variety of biologically important peptides and make the cis-amide 
isomer more energetically accessible for recognition and binding to a given receptor. 
Proline is the only naturally occurring amino acid that leads to N-alkylated amides. 
Many other cases exist where either local, or global interactions, favour a cis-amide 
configuration in a biologically active peptide. The biological activity of Angiotensin 1, 
for example, has been shown to coincide with the isomerization of the His-Pro amide 
bond to the cis configuration.37 Compounds 20,43 21 and 22,44 are examples of 
dipeptide analogues that mimic cis-amide bonds. 
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The development of cis-amide bond analogues that mimic this form of biologically 
active conformation is an important general technique in peptidomimetic design. It is 
with this in mind that we propose a new class of conformationally restricted cis-amide 
bond analogue incorporating a Freidinger lactam arrangement. Previously reported 
Freidinger lactams containing a cis-like amide constraint have proved to be scarce. Two 
examples ofthese are shown below. 
Peptide azides such as 24, a reduced form of Cys-Cys, have been of particular interest, 
as hexapeptide analogues containing such units show substance P antagonistic activity 
up to ten times that of the original peptide. 
It is with the scarcity of cis-amide mimics of this type in mind, that we propose a new 
class of conformationally restricted cis-amide bond analogue incorporating a Freidinger 
lactam arrangement. The proposed system is based on a lactam and is illustrated in 
Figure 5, along with the analogous section of peptide backbone it is intended to mimic. 
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Figure 5 Target cis-Amide Bond Mimics (DMB=2,4-dimethoxybenzyl) 
The target peptidomimetics bridge the peptide backbone as shown, restricting the 
otherwise free rotation about the peptide bond (indicated by \If). The result is a five-
membered lactam ring, containing the peptide bond, being incorporated into a peptide 
sequence with the peptide bond being locked in the cis-like configuration. Compounds 
of this type have been shown to be good cis-amide bond mimics due to the sp2 nature of 
the ene-lactam double bond locking the lactam ring in a planar configuration. 
An outline of the proposed synthesis of the target molecule is shown in Scheme 1. 
Key steps in this sequence include the conversion of acid chloride 69, to the ~-keto ester 
71 via an acyl Meldrum's acid intermediate 70. In this case ethanol was used as a 
quenching agent to give the ethyl ester, but, as will be shown, it is also possible to use 
amines as a way for producing ~-keto amides. This provides a method for extending the 
peptide chain in the C-direction in one easy step. The conversion of 71 to the cyclic 
acylated enamino esters 77, and 79, occurs by way of an imine/enamine intermediate, to 
form the five-membered substituted cyclic lactam ring. These two steps form the basis 
of this synthesis and will be described in greater detail in the following chapters. 
Preparation of compounds 77 and 79 also allows the possibility of subsequent 
reduction of the ene-lactam double bond to form a dipeptide analogue more closely 
resembling the parent peptide it is intended to mimic. Hydrolysis of both the N and C 
protecting groups also gives rise to the potential for chain extension in both the Nand C 
directions. 
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Although this will not be discussed in great detail here, brief mention will be made to 
future synthetic possibilities, with this being an important goal ofthis work. 
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Since the first example of the Claisen condensation was discovered more than a 
century ago, ~-keto esters have been very important intermediates in organic synthesis. 
This importance can be attributed to such compounds containing a unit composed of two 
different electrophilic carbonyls, and two carbons, a to the carbonyls, which can be 
made to react selectively under suitable conditions.46 This makes them valuable tools in 
the synthesis of a wide variety of molecular systems. A simple example of this use is in 
the preparation of Thienamycin,47 a potent ~-amino antibiotic, where the starting 
compound for the synthesis is a ~-keto ester of the type described here. This chapter 
describes the synthesis of the succinic acid-derived ~-keto ester 23, via a general 
Meldrum's acid method, in preparation for its use in the synthesis of unsubstituted 
enamino esters of type 55 and· 56. 
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55 R=Et, X=CH3 
56 R=Et, X=DMB 
Also in this chapter, extension ofthese principles will be applied to the synthesis of the 
aspartic acid derived ~-keto ester oxazolidinone 28. This serves as a precursor to the 3-
substituted enamino esters 59 and 61, which have the potential for peptide chain 
extension in both theN and C directions (Figure 7). 
59 R=Et, X=Me 
61 R=Et, X=CH2C02Et, 
Figure 7 
Compounds of this type are examples of five-membered Freidinger lactams where the 
N-substituted amide bond is locked in a cis-configuration. Incorporation of enamino 
esters into an appropriate substrate peptide has been shown to be a successful strategy 
for enhancing recognition by a target enzyme. 
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A related procedure has been reported by Pak et a/,43 in which an acyl Meldrum's acid 
intermediate was refluxed with various amines, in toluene, to give the corresponding f)-
keto amide. The synthesis of compounds of this type, allows the incorporation of an 
amide bond, with chain extension in the C-direction, in one easy step. This has proved 
valuable in the synthesis of lactams of type 63 and 64, where the ester group is replaced 
with a desired amine or amino acid (Figure 8). 
0 0 MeO~N~R----0£0--N~R 
0 0 H 11 H 
24 
X 
Figure 8 
63 R=CH2C02Et, X=CH3 
64 R=CH2C02Et, X=DMB 
The Meldrum's acid reaction 
In 1908 A. N. Meldrum observed that malonic acid and acetone reacted in a cold 
acetic anhydride-sulphuric acid medium, to eliminate water and form a crystalline 
product.49 Meldrum's acid, as it was called, was later characterised and found to be the 
cyclic bifunctional ester 2,2-dimethy 1-1 ,3-dioxane-1, 4-dione. 50 
~:x 
0 
Meldrum's acid 
In 1978 Yonemitsu et al demonstrated that upon acylation with various acyl chlorides, 
meldrum's acid could be used to give the corresponding acyl Meldrum's acids, which 
readily underwent alcholysis to give f)-keto esters in good yield. 51 They further showed 
that Meldrum's acid readily reacted with acid chlorides even in the absence of a strong 
base, a requirement of many other methods of the time. This reactivity was due to its 
enhanced acidity (pKa 4.97) and allowed acylation to occur under relatively mild 
conditions. Treatment of Meldrum's acid with a mild base such as pyridine, led to the 
deprotonation at the methylene carbon to give a stable anion. The anion is stabilized by 
delocalization through both carbonyls. This anion of Meldrum's acid was shown to 
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carry out nucleophilic attack on an acid chloride to give an acyl Meldrum's intermediate 
(Figure 9). 
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Figure 9 Formation of an acyl Meldrum's acid intermediate 
Alcholysis of this intermediate led to the elimination of acetone and carbon dioxide to 
give the B-keto ester in good yield. This was subsequently presented as a general and 
efficient method for the synthesis of B-keto esters of type RCOCH2C02R' (Scheme 2). 
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Scheme 2 Formation of B-keto esters from acid chlorides via an acyl Meldrum's acid 
intermediate 
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Synthesis of J3-keto esters 
Consequently, ~-keto ester 23, the starting compound for the synthesis of target 
enamino esters 55 and 56, was prepared from the acid chloride 21, according to the 
procedure outlined by Yonemitsu eta! (Scheme 3).51 
A solution of carbomethoxypropionyl chloride 21 (1 equivalent), in dichloromethane, 
was treated with Meldrum's acid (1.1 equivalent) and pyridine (2 equivalents), and 
stirred at 0° C for 50 min, and then at 20° C for 45 min to give the acyl Meldrum's acid 
intermediate 22. 
The acyl Meldrum's acid 22 was refluxed in ethanol for 2.5 hr, whereupon the solvent 
was removed and the residue given a base wash (NaHS04) to give the ~-keto ester 23 in 
high yield (84%), and purity. 
Meo-c>r-cl 
0 0 
21 
meldrum's acid I 
/pyridine 
MeO'ooi=:~ 
22 ° 
I EtOH /heat 
0 MeO~OEt 
0 0 
23 
Scheme 3 Synthesis of Succinic Acid-derived ~-Keto Ester 23 
The acid chloride used in this reaction was prepared :from the corresponding acid, on 
reaction with oxalyl chloride (5 equivalents) and DMF, in dichloromethane. This was 
employed in the subsequent preparation of all acid chlorides described here and has the 
added advantage of producing gaseous by-products, which can be easily removed. The 
mechanism for the formation of 23 is shown ·in Figure 10. Note that DMF is used 
catalytically to generate a species more susceptible to chlorination. 
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Figure 10 Preparation of an Acid Chloride from an Acid using Oxalyl Chloride and 
DMF 
An extension of these principles allowed the synthesis of the aspartic acid-derived ~­
keto ester 28 (Scheme 4), an oxazolidinone compound used in the preparation of the 
substituted enamino esters 59 and 61 (Figure 7). The starting compound for this 
pathway was the acid chloride 26, which was itself prepared from the reaction of the 
corresponding acid 25, with oxalyl chloride (5 equivalents) and DMF, in 
dichloromethane. 
The acid 25 was obtained via the procedure set forth by Scholtz and Bartlett 52, 
whereby a solution of N-benzyloxycarbonyl (Cbz)-(S)-aspartic acid, paraformaldehyde 
(2 equivalents) and PTSA (0.06 equivalents), in benzene, was refluxed for 1 h with 
azeotropic removal of water. 
The resulting oxazolidinone 25 effectively protects the a-carboxylic acid group of S-
Cbz-aspartic acid, and allows subsequent reactions to occur at the unprotected side chain 
~-carboxylic acid. Conversion of the acid to the acid chloride 26 allows its use in the 
preparation of the ~-keto ester 28 (Scheme 4), via the same method described above for 
the succinic acid-based ~-keto ester 23 (refer to Scheme3). 
That is, acid chloride 26 (1 equivalent), pyridine (2 equivalents), and Meldrum's acid, 
dissolved in dichloromethane, were stirred at 0° C for 50 min, then at 20° C for 45 min. 
The solvent was removed under reduced pressure and the residue was refluxed in 
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ethanol for 2.5 h. Purification by radial chromatography gave the ~-keto ester 28 as a 
yellow oil (87%). 
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Scheme 4 Synthesis of Aspartic Acid-derived ~-Keto Ester 28 
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Synthesis of ~-keto am ides 
In 1992, Pak et al reported that the mel drum's acid methodology, used by Y onemitsu 
et al for the synthesis of ~-keto esters, could be applied to the preparation of ~-keto 
ami des. 48 These compounds have also proved to be very versatile intermediates in 
organic synthesis. There are a number of synthetic methods for the preparation of these 
compounds, however many of these suffer from limitations of one kind or another. Pak 
et al showed that by using an amine in place of an alcohol, the direct aminolysis of acyl 
meldrum's acid afforded a convenient and versatile synthesis of ~-keto arnides (Figure 
11). 
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Figure 11 Pak et al' s Methodology for the Synthesis of ~-Keto Arnides 
Among the many amines used by Pak and his colleagues, was glycine ethyl ester 
(H2NCH2C02Et). Amination of acyl Meldrum's acid using this amine gave a ~-keto 
amide containing a carboxyl-protected amino acid residue. Application of this method 
has been used here in the synthesis of the ~-keto amide 24 (Figure 12). 
0 MeO~N-COEt 
0 0 H 2 
24 
Figure 12 
-
O~N-C02Et 
1 H 
X 
63 X=CH3 
64 X=DMB 
This has been used in the preparation of lactams of type 63 and 64, where extension of 
· the molecule in the C-direction, in the form of an amide bond, has already been 
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achieved. This also allows the possibility of incorporating various ammo acids or 
' peptide sequences into the molecule to allow a closer resemblance to adjacent residues 
in the parent peptide, a factor of great importance in peptidomimetic design. 
Compounds of this type can also be prepared from the cyclic enamino ester 
equivalents 55 and 56 (Figure 6), via hydrolysis of the ethyl ester and subsequent 
coupling of an amino acid. However, where possible, direct aminolysis of Meldrum's 
acid negates the need for this step and leads to a reduction in the total number of steps in 
the synthesis of the desired product. 
Therefore, the preparation of ~-keto amide 24 from the corresponding acid chloride 
21, was carried out according to the procedure described by Pak et al (Scheme 5). A 
solution of the acid chloride 21 (1 equivalent), in dichloromethane was treated with 
meldrum' s acid (1.1 equivalents), and pyridine (2 equivalents) and stirred at 0° C for 50 
min, and at 20° C for 45 min, to give the acyl meldrum's acid intermediate 22. 
A solution of acyl Meldrum's acid 22, glycine ethyl ester hydrochloride (1.1 
equivalents) and triethylamine (1.1 equivalents)~ in benzene, was then refluxed for 4 h. 
Purification by radial chromatography gave the ~-keto amide 24 as a yellow oil (47%). 
MeO~Cl + 
0 0 
0 
Meo--chJLN---co Et 
0 0 . H 2 
24 
iii 
-
Scheme 4 i pyridine, dichloromethane, ii HCl.H2NCH2C02Et, Et3N, iii 150° C/1 mm 
By combining both Yonemitsu's and Pak's methodologies, this now gave us a 
convenient method for the preparation of succinic acid-derived ~-keto esters and ~-keto 
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amides, via a common intermediate 22. By varying the nucleophile used to quench the 
acyl Meldrum's acid, it was possible to extend the molecule via an ester linkage or an 
amide linkage (Figure 13). In this case, extension in the form of an amide was 
preferable, as it allowed direct incorporation of a C-protected amino acid into the 
molecule. However, extension of the molecule via an ester linkage was still an attractive 
option due to it being a very high yielding reaction. 
0 
Meo--0--JloEt 
0 0 
23 
0 
Me0--0--Ji-N-R 
0 0 H 
24 
Figure 13 Synthesis of Succinic Acid-derived B-Keto Esters and B-Keto Amides from a 
Common Intermediate 22 
Examination of these processes led us to believe that a similar method could be 
adopted for the preparation of the corresponding aspartic acid-derived B-keto amide 
oxazolidinone 29 (Scheme 6). 
z z 
N 0 N i:>{O HCI.gjOEt (Q-)_5 0 _ x-,~0 N-coEt OHO 0 0 0 H 2 
0 
26 27 29 
Scheme 6 
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Again this would invoke the use of an acyl Meldrum's acid intermediate, and involve 
direct amination as before. However, when this process was attempted, it was 
unsuccessful and gave only a trace of the desired product. This was reasoned to occur 
due to the oxazolidinone ring acting as an activated ester and hence being the preferred 
site of attack for aminolysis. This led to a fragmentation of the molecule, with no 
recognizable products being observed by NNIR. This process was repeated several times 
without success. 
Despite the unsuccessful nature of this reaction, the synthesis of the aspartic acid 
derived B-keto ester 28 still gave a convenient route to the formation of enamino esters 
(Figure 14). Removal of the ester group and addition of an amino acid via a peptide 
coupling reaction could still be carried out at a later stage. 
Figure 14 
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Structural Assignment and NMR data 
The 1H NMR spectra of the succinic acid-derived B-keto ester 23, and B-keto amide 
24, gave rise to standard proton coupling signals and hence will not be discussed in 
detail here. A simple numbering system was used for both compounds to allow easy 
comparison of each proton signal (this differs from the systematic name in the case of 
24). The methylenes at positions 2 and 3 each gave rise to a triplet due to mutual spin-
spin coupling. A characteristic singlet was observed for the two protons at position 5, 
they being adjacent to two carbonyls, and, therefore not available for short-range proton-
proton coupling. The two protons at position 8 in compound 24, appeared as a doublet 
du~ to coupling with the adjacent amide proton. 
Chapter 3 Svnthesis of B-keto esters and amides 
J Nil L .. ' 
-~----p-~--~·-··r···-·-·-- .. --. ·- r I ' - ~-- . ,. ·-·. 
7 6 s 
~leO 
~ol\'t'tll 
51 
-~--, 
ppm 
.. - '--,-·-·· ..... . 
z 
In the preparation of the aspartic acid-derived ~-keto oxazolidinone 28, the 
introduction of a stereogenic centre into the molecule gave rise to the possibility of 
diastereotopic protons. That is, protons attached to the same carbon, which exist in 
different electronic environments due to the chiral nature of the molecule. In the case of 
28, C4 is a stereogenic centre which leads to the two protons associated with (H2)2 
being in different environments, as are the PhCH2 protons of the Cbz group. Hence they 
are referred to as diastereotopic. This gives rise to a splitting of the signals associated 
with each proton. As each proton can exist in either of two spin states, a doublet of 
doublets results, with the inner peak's intensity of each increasing, the smaller the 
frequency difference is between the two protons. This is commonly referred to as an AB 
qu~et (ABq)and is evident in the spectra below. 
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rn~'~· () 28 ()' . _____ll 
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() () 
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The protons associated with C4CH2 also display signal splitting, as they too are 
diastereotopic. It is clear that both are associated with the same carbon, however they 
have been reported here as 2 doublets due to the broad nature of the signals. In this 
compound, the resonance associated with COCH2CO appeared as a broad singlet, but, as 
will be discussed later, in compounds where substitution of the oxazolidinone is 
introduced, signal splitting occurs here also. The CH2 of the ethyl ester, although part of 
an ester linkage, is too far away from the chiral centre to display any signs of the 
environment of the protons being affected. Hence, splitting of this signal does not occur. 
Summary 
Using the meldrum's acid method developed by Yonemitsu et al, it was possible to 
synthesize ~-keto ester 23 (Scheme 3), in preparation for its reaction with an amine to 
form simple unsubstituted enamino esters of type 55 and 56. This method was also 
applied to the preparation of the aspartic acid derived ~-keto ester oxazolidinone 28 
(Scheme 4). Preparation of 23 and 28 were carried out under relatively mild conditions, 
and gave a convenient and consistently high yielding method for synthesis of 
compounds of this type. 
Extension of these principles using the methodology developed by Pak et al, led to the 
preparation of ~-keto amide 24, This allowed the incorporation of an amide bond, with 
chain extension in the C-direction, in one easy step. Although preparation of the 
corresponding aspartic acid derived ~-keto amide proved unsuccessful, due to the 
reactivity of the oxazolidinone ring, this method still afforded a convenient method for 
the preparation of simple ~-keto amides. 
Compounds 23 and 24 gave rise to characteristic 1H NMR resonances, with the 
introduction of a stereogenic centre into compound 28 leading to signal splitting, due to 
the nature of a number of the protons being diastereotopic 
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Enamino esters and enamino amides are sub-classes of an important group of 
compounds known as ene-lactams. Ene-lactams are found in nature, in both plant and 
animal life, and serve a number of important purposes. An example of this is in the case 
of Lyngbya majuscula, 53 a toxic shallow water variety of marine blue algae. Certain 
strains of this algae are known to be responsible for the contact dermatitus known as 
'swimmers itch'. Samples of Lyngbya majuscula containing such irritants have also 
been found to contain a class of compounds known as Pukeleimides. Exemplified by 
pukeleimide A 30, pukeleimide C 31, and pukeleimide E 32/4 pukeleimides are an 
example of a naturally occurring class of compounds containing an ene-lactam unit. 
OH 
ohJp-oMe ~ h Me 0 
30 
obJp-oMe ~ h Me 0 
32 
There are numerous other examples in nature where compounds of this type, 
containing one or more ene-lactam units, can be found. Perhaps the most widespread 
and important examples in which this functionality is utilised, is in the skeleton of 
macrocyclic tetrapyrroles of the chlorin, isobacteriochlorin and corrin oxidation level. 55 
Members of this latter class serve important biological functions as vitamins, co-factors, 
and light absorbing pigments. Compounds such as hemoglobin, myoglobin, 
cytochromes and chlorophylls are derived from this class and contain tetrapyrrol 
components that form the essential basis for their biological function. A good example 
of this are biliproteins, 56 a family of chromophores consisting of a linear tetrapyrrole 
covalently bound to a protein. Found in algae, cyanobacteria, cryptophytes, mosses and 
other higher green plants, biliproteins are extremely important in photosynthesis and are 
involved in the photoregulatory . functions, such as photomorphogenesis, of many 
species. As such they have been of considerable interest for over a hundred years. This 
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may also be, in part, a result of the many brilliant and intense colours associated with 
compounds of this type. Rings A (33,34) and D (35,36) of the biliproteins are ene-
lactams. 
0 
0 
N 
H 
N 
H 
33 R=Et eg phycochromes 
34 R=CH=CH2 eg phytochromes 
- protein binding sites 
R 
0 
.... ~ 
N 
H 
35 R=H eg phycoerythrobilin 
36 R=Me eg aplysiaviolin 
Pigments such as 33 and 34, are important for photosynthesis and are found in nearly 
all forms of plant life as well as photosynthetic organisms. 57 These so-called accessory 
light-harvesting pigments assist chlorophylls a and b, the major light gathering pigments, 
in trapping light energy for use in the cell. These accessory pigments, along with others, 
are also responsible for the magnificent colours associated with autumn. They persist 
longer after leaf death than the more labile chlorophylls and account for the many 
yellow, orange and red leaf colours seen at this time of the year. 
In some cases, members of the animal kingdom have taken advantage of such plant 
pigments to aid in their survival. Aplysia, a species of sea hare with a voracious appetite 
for red algae, when disturbed, will excrete a thick, purple ink from a specialized ink 
gland. Aplysiaviolin 36, as it was called, turned out to be a modified form of 
phycoerythrobilin 35, the red pigment associated with the red algae off which it fed. 58 
As well as being important components in nature, ene-lactams have also proved to be a 
valuable functionality in natural products chemistry. They have been utilized in either 
free or protected form, in the synthesis of many compounds such as prostaglandin 
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analogues, 59 y-lactam antibiotics,60 peptide mimics,61 angiotensen II antagonists,62 and 
many other biologically active compounds. An example of this was in the first total 
synthesis of cobyric acid 41, a naturally occurring corrin and a known precursor of 
vitamin B12 . Early work by Woodward63 and Eschenmoser, led to the publishing, by 
Eschenmoser et al, of an improved synthesis of 41 which made use of ene-lactam 
derivatives 37-39, and pyrroline 40, for the assembling of the corrin skeleton.64 
C02 Me 
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Me02c~= 0 
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This has led to the use of ene-lactams, in the synthesis of a wide variety of biologically 
active compounds. Cyclic enamino esters have proven to be valuable intermediates in 
these processes, a few of which are shown below. 53' 65, 66, 60, 67 
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Therefore, cyclic enamino esters represent an attractive synthetic target. Traditionally, 
cyclic enamino esters have been prepared from corresponding imides, via a Wittig 
(pathway a, Scheme 7), 68' 69' 70 Reformatsky (pathway b, Scheme 7), 70' 71 or Grignard 
reaction (pathway c, Scheme 7).70• 71 
~ 
c. 'ROC=CMgBr/HCl 
Scheme 7 
ri.)n 9 
O~N~OR' 
R 
However, reactions of this type suffer from low yields, harsh reaction conditions, and 
the tendency to undergo undesirable side reactions, such as his-adduct formation e.g. 42 
· , and subsequent isomerization to pyrroles e.g. 43. 
More recently, it has been reported that cyclic enamino esters can be prepared from the 
reaction of an enol lactone, e.g. 46, with an amine, via an insertion reaction (Scheme 
8).61 Initially, enollactones oftype 46 were prepared from the corresponding anhydride 
45, via a Wittig reaction. However, synthesis of anhydrides of this type was not trivial 
and required large-scale preparation from the corresponding diacid 44, something that 
was not readily available. Subsequent distillation of the anhydride product 45, also 
presented a problem thereby making preparations of such compounds quite difficult. 
Scheme 8 
In 1993, Abell et al oyercame many of these problems by reporting a modified use of 
the classic Wittig reaction. 61 This modification, the Schlosser modification, or a-
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substitution plus carbonyl olefination v1a ~-oxido phosphorus ylides (SCOOPY) 
reaction, involved the lactonization of a keto acid phosphorane, eg 49, to give the 
corresponding enol lactone 51 in high yield (Scheme 9). The introduction of an amine 
or amino acid into the enol lactone, via an insertion reaction, gave the cyclic acylated 
enamino ester 53. The keto acid phosphorane 49, was prepared from the alkylated 
oxazolidinone 48, upon treatment with Ph3P=CHC02Et. The methodology for this 
process is illustrated in Scheme 9, and provided a general and convenient synthesis of 
cyclic enamino esters. 
z 
HN ,.·-Ph o~C02Et 0 
51 
Scheme 9 i, Ph3P=C02Et, CH2Ch, oo C 1.5 h, 20° C 4.5 h; ii, LiOH, THF, MeOH 
reflux 4 h; iii, Et3N, CH2Ch, 0-20° C; iv, gly-OEt.HCl, Et3N, CH2Ch, 20° C 18 h; v, 
PTSA, 1,2-DCE reflux 3.5 h 
Along with this work, it has also been shown that cyclic enamino esters can be 
prepared from ~-keto esters.60 This involves the treatment of a ~-keto ester with 
RNH2.HCl/Et3N, followed by heating under reduced pressure. A cyclization process 
occurs by way of an imine/enamine intermediate to give cyclic enamino esters of the 
type shown below (Scheme 1 0). 
Scheme 10 
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It immediately became clear that the application of this process to a 3,3-disubstituted 
~-keto ester oxazolidinone, derived from the corresponding alkylated oxazolidinone 48, 
would allow a more direct synthesis of cyclic enamino esters of type 53. The N-
methylated and N-protonated forms would give rise to Freidinger lactams that could be 
incorporated into a peptide sequence to mimic a cis-amide bond. _ 
This chapter describes the use of this method in the preparation of succinic acid-
derived, non-substituted compounds of this type, where the amide nitrogen is alkylated 
(Scheme 11). 2,4-Dimethoxybenzylamine (DMB) was used as a protected form of 
ammonia which, if desired, can later be removed to give the protonated form of the 
amide nitrogen. 
0 MeO~OEt 
0 0 2. heat O~OEt I 
R 
55 R=CH3 
56R=DMB 
D MB=2,4-dimethoxybenzyl 
Scheme 11 
Application of this technique was also applied to the preparation of succinic acid-
derived enarnino amides, using ~-keto amides as a precursor (Scheme 12). 
DMB=2,4-dimethoxybenzyl 
Scheme 12 
63 R=CH2C02Et, R'=CH3 
64 R=CH2C02Et, R'=DMB 
This allows extension of the molecule in the form of an amide bond while agam 
negating the need for the ester cleavage and peptide coupling reactions referred to 
earlier. 
Also in this chapter, the ~-keto ester route is extended to the synthesis of aspartic acid 
derived 3-substituted enamino esters 59 and 61 (Scheme 13). These compounds were 
prepared from the oxazolidinone ~-keto ester 28 and have the potential for chain 
extension in both the Nand C directions. 
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The final synthesis of 3,3-disubstituted cyclic enammo esters will be discussed m 
chapter 5. 
Synthesis of cyclic enamino esters 
The preparation of P-keto esters has been described previously in chapter 3 (Schemes 
3 and 4). The P-keto ester 23, the starting compound for the synthesis of enamino esters 
55 and 56 (Scheme 11 ), was prepared from the acid chloride 21 according to the 
procedure reported by Yonemitsu et a! (see chapter 3). This method involved the 
alcholysis of an acylated Meldrum's acid intermediate 22 to give the B-keto ester 23 in 
good yield (Scheme 14). 
0 . 
MeO--{)---ci-MeO~~~-MeODJoEt 
o o ~ Hd }--o o o 
0 . 
21 22 23 
Scheme 14 
In 1988, Hashiguchi et a!, in synthesizing analogues of Thienamycin and other 
carbapenums, showed that cyclic enamino esters could be prepared by refluxing, with 
azeotropic removal of water, a toluene solution of a P-keto ester, with an amine.60 
Heating of the residue, under reduced pressure, induced the formation of the 
corresponding cyclic enamino ester. Hence enamino esters 55 and 56 were prepared by 
a similar method to that reported by Hashiguchi et a!. 
The enamino ester 55 was prepared by refluxing a solution of the B-keto ester 23 in 
1,2-dichloroethane, containing methylamine hydrochloride (9 equivalents), and 
triethylamine. After 90 min, the solution was filtered and the solvent was removed 
under reduced pressure .. The residue was then heated at 150° C, under reduced pressure, 
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(1 mm of Hg) for 1 h. Purification by radial chromatography gave 55, as a white solid, 
in 26% yield. 
In an attempt to increase the yield of this reaction, an alternative method for the 
synthesis of 55 was attempted, involving the use of the free amine rather than the 
hydrochloride salt (Scheme 9). A solution of methylamine in 1,2-dichloromethane was 
used and refluxed with the ~-keto ester 23 in 1 ,2-dichloroethane in a similar manner as 
before. Purification of the crude product by radial chromatography gave the enamino 
ester 55, however, in a similar yield to that obtained using the previous method. Hence, 
the use of the free amine in the reaction mixture was seen as no great advantage. In fact 
it was seen as somewhat of a disadvantage due to the free amine being extremely 
volatile and difficult to handle. Therefore, where possible, the hydrochloride salt was 
used in such reactions. 
Scheme 15 
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Preparation of 55 is therefore carried out in a two step process vm an enamme 
intermediate. An 1H NMR spectrum of this intermediate indicated that both theE and Z 
isomers were present. However, this did not appear to affect the overall reaction as, 
upon heating at 150° C at 1 mm Hg, the target enamino ester 55 was formed relatively 
cleanly. Isolation of intermediates of this type has proved difficult and no attempt to 
isolate the enamine intermediates was made here. Purification of the final product by 
radial chromatography yielded 55 exclusively as the E isomer, confirming that isolation 
of the enamine intermediate was not necessary. 
Mechanism of enamino ester formation 
The mechanism for the formation of enamino ester 55 involves two stages (Figure 15). 
First, the formation of an enamine intermediate 54 via attack of the free amine, 
generated in situ, on the ~-carbonyl of the ~-keto ester 23. Secondly, heating of the 
residue to bring about attack of the enamine N on the methyl ester carbonyl. This 
second stage is a one step process and leads to ring closure and the formation of the 5-
membered enamino ester ring. 
9:)0 ~0 1\ 
0
}---oEt MeO~ OEt MeO OEt MeO-i _ r 
= 0 0~-H ~ 0 ~ 
H ~ ~ 
HN-Me ~~ 0 A }--oEt 
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Me 
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.......,_ 1\ -'}-OEt 
Mea~, _j=-1 (o\_~-Me - O~OEt I 
H 
54 
Me 
55 
Stage 2: 150° C at 1mm Hg 
Figure 15 Mechanism of Formation ofEnamino Ester 55 
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Generation of the enamine intermediate 54 also gtves nse to the possibility of 
imine/enamine tautomerism. However, as no direct evidence of this effect was observed 
by 1H NMR in the preparation of 55 and 56, it will not be discussed further at this stage. 
Imine/enamine formation will be discussed in more detail later in the preparation of 3-
substituted enamino esters 59 and 61, where the 1H NMR spectra of the intermediates 
are complex and unable to be assigned. This suggests that not only were the E and Z 
enamines present, but the corresponding E and Z imines as well. 
The enamino ester 56 was prepared in a similar manner to that described for 55, and 
involved the treatment of 23 with 2,4-dimethoxybenzylamine hydrochloride (1.2 
equivalents) and triethylamine (1.2 equivalents) (Scheme 16). 
Scheme 16 
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Purification by radial chromatography gave 56 as a white solid in 42% yield. The 
mechanism for this reaction is analogous to that described in figure 15 for 55, and gives 
theN-protected enamino ester 56 exclusively as theE isomer. 
Synthesis of 3-su bstituted enamino esters 
The same methodology outlined for the preparation of simple enamino esters 55 
(Scheme 15) and 56 (Scheme 16), was used to prepare 3-substitiuted enamino esters 59 
and 61. The starting compound for these syntheses was the oxazolidinone ~-keto ester 
28 (Scheme 17). 
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Scheme 17 Synthesis of Aspartic Acid-derived Enamino Esters 59 and 61 
Enamino esters 59 and 61, were prepared by refluxing, with azeotropic removal of 
water, a solution of the ~-keto ester 28 in 1,2-dichloroethane, with either methylamine 
(20 equivalents), or glycine ethyl ester hydrochloride (3 equivalents) and triethylamine 
(3 equivalents). After 90 min, the mixture was filtered and the solvent was removed 
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under reduced pressure. By analogy to the succinic acid-based systems 55 and 56, the 
compound present at this stage should be the enamines 57 and 60 (Scheme 17). 
However, the 1H NN1R of both intermediate residues were complex and unable to be 
assigned. This suggested a mixture of E- and Z-enamines, and possibly also the 
corresponding E- and Z-imines, had formed (Figure 16). 
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Figure 16 Imine/Enamine Tautomerism exhibited by 57 and 60 
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This did not appear to affect the overall reaction as upon heating the residues at 150° 
C, under reduced pressure ( 1 mm of Hg), for 1 h, the target enamino esters were formed 
relatively cleanly. Purification by radial chromatography gave 59 and 61, as yellow oils, 
in 70% and 63% yields respectively. 
Mechanistically, the formation of enamino esters 59 and 61 involves two steps. Figure 
17 illustrates these steps in the formation of enamino ester 59. The first step involves 
the formation of the 5-membered enamino ester ring, via attack of the enarnine N on the 
oxazolidinone carbonyl (step a, Figure 17), while the second step leads to the loss ofthe 
formaldehyde protecting group (step b, Figure 17). 
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Figure 17 Mechanism of Formation of Aspartic Acid-derived Enamino Ester 59 
Elimination product 
66 
Attempts to synthesis the corresponding 3-substituted enamino ester using 1,2-
dimethoxybenzylamine were unsuccessful. Use of both the free amine, and the 
protected hydrochloride salt, did not allow formation of the desired enamino ester. As in 
the case of ~-keto amide formation, this was postulated to be due to the preferred attack 
of the amine on the oxazolidinone ring. This was subsequently confirmed by the 
isolation of a 3-substituted succinimide derivative 62, where the alkyl side chain of the 
enamino ester had been eliminated. 
z 
HN 
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n MeO 0 OMe 
62 
Purification by radial chromatography gave 62 as a yellow oil in 77% yield. Two 
proposed mechanisms for the formation of this elimination product are outlined in 
Figure 18. 
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Figure 18 Two Proposed Mechanisms for the formation of Elimination Product 62 
Synthesis of enamino amides 
67 
This technique was also applied to the preparation of enamino amides from the 
corresponding ~-keto amide, in the event it would lead to a convenient method for chain 
extension in the C-direction. Synthesis of these compounds was achieved via the same 
conditions as that for enamino esters 63 and 64, only using the ~-keto amide 24 as the 
starting compound (Scheme 18). 
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The ~-keto amide 24, the starting compound for the synthesis of enamino amides 63 
and 64, was prepared from the acid chloride 21, via a mel drum's acid reaction with 
glycine ethyl ester hydrochloride (Scheme 5, Chapter 3). 
{ 
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Me 
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MeO ~ OMe 
1
150° Cat 
lmmHg 
OnJN ____ COEt nH 2 
MeO ~ OMe 
64 
Scheme 18 Synthesis ofEnamino Amides from ~-Keto Amides 
Enamino esters 63 and 64, were subsequently prepared by refluxing, with azeotropic 
removal of water, a solution of ~-keto amide 24 in 1,2-dichloromethane, with 
methylamine (20 equivalents), or 1,2-dimethoxybenzylamine hydrochloride (3 
equivalents) and triethylamine (3 equivalents). After 90 min, the solution was filtered 
and the solvent was removed under reduced pressure. The residue was then heated at 
150° C, under reduced pressure (1 mm of Hg), for 1 h. Purification by radial 
chromatography gave the enamino amides 63 and 64, as white solids in 25% and 39% 
yields respectively. 
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Structural assignment and NMR data 
The structure of enamino esters 55, 56, 59, 61 and enamino amides 63 and 64, were 
primarily assigned on the basis of 1H NMR, 13 C NMR, IR spectroscopy, and high 
resolution mass spectrometry. Figure 19 illustrates the structural assignment of enamino 
esters 55, 56, 59, 61 and enamino amides 63 and 64. 
Figure 19 
55 R=OEt, R'=Me 
56 R=OEt. R'=DMB 
63 R=NHCH2C02Et, R'=Me 
64 R=NHCH2C02Et, R'=DMB 
DMB=2,4-dimethoxybenzyl 
1 H NMR spectroscopy was used to assign the EIZ configuration. The most diagnostic 
resonances were those due to (H4)2 and =CH. The ethyl ester in theE configuration is 
known to deshield (H4)2 in succinimide-based enamino esters.72 Therefore, enamino 
esters 55, 56, 59, 61, and enamino amides 63 and 64, were assigned theE configuration 
on the basis of the downfield shift of (H4)2 being similar to known literature compounds 
of this type.70' 73 Both (H3)2 and (H4)2 resonances appear as coupled triplets, with (H4)2 
displaying additional signal splitting due to long range coupling with the =CH proton. 
Table 3 summarizes the 1H NMR and 13C NMR data of enamino esters 55, 56 and 
enamino amides 63 and 64. 
Compound 8 (H3)2 ,m 8 (H4)2 ,m 8 =CH ,t 8=CH 8C5 
55 2.55 3.23 5.18 91.6 160.6 
56 2.63 3.25 5.32 92.6 160.4 
63 2.53 3.28 5.12 93.0 166.6 
64 2.60 3.28 5.17 94 166.8 
Table 3 Significant 1H NMR and 13C NMR of succinic acid-derived enamino esters 55, 
56 and enamino amides 63 and 64. 
In the case of aspartic acid-derived 3-substitiuted enamino esters 59 and 61 (Scheme 
17), the introduction of a stereogenic centre at C3 gives rise to an increase in complexity 
of the resonances associated with (H4)2, and CH2C02Et where R'=CH2C02Et. The 1H 
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NMR and l3C NMR spectra indicated a single isomer in both cases. These were both 
assigned the E configuration as the (H4)2 resonances were in a characteristic downfield 
position, reflecting the deshielding effect of the C02Et group. Characteristic 1H NMR 
and l3C NMR data for the 3-substituted enamino esters 59 and 61 is summarized in 
Table 4. 
Compound R' 8 H3 8 (H4)a 8 (H4)b 8 =CH 8 =CH 8 C5 
59 Me 4.38 3.05 3.82 5.19 93.0 166.8 
3.11 3.91 5.12 93.5 166.5 
Table 4 Significant 1H NMR and 13C NMR data of the aspartic acid-derived enamino 
esters 59 and 61. 
Summary 
Using the method described by Hashiguchi et al, for the synthesis of cyclic enarnino 
esters, it was possible to prepare succinic acid-derived enamino esters 55 and 56, as well 
as the corresponding enamino amides 63 and 64. The starting compounds for these 
preparations were the ~-keto ester 23, and the ~-keto amide 24 respectively. The 3-
substituted enamino esters 59 and 61, were prepared via the same method from the 
aspartic acid derived ~-keto ester 28. Enamino esters 59 and 61 are examples of 3-
substitiuted Freidinger lactams where the amide bond is locked in a cis-like 
conformation (refer Chapter 2). 
Synthesis of enamino esters of this type proceeds via an imine/enamine intermediate, 
before cyclizing to give the five-membered lactam ring. The assignment of these 
compounds exclusively as theE isomer was based on 1H NMR data and comparison of 
that data with known literature compounds. 
Chapter 5 Synthesis of phenylalanine derived 3,3-disubstituted enamino esters 71 
Synthesis of 
phenylalanine-derived 
3,3-disubstituted 
n mino esters 
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This chapter describes the synthesis of phenylalanine derived 3,3-disubstituted 
enamino esters 77 and 79. These compounds have the potential for incorporation into a 
peptide sequence to mimic a cis-amide bond. Enamino esters 77 and 79 represent a new 
class of conformationally restricted amino acid analogues for use as a potential tool in 
enzymatic studies (see Chapter 2). 
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The 3,3-disubstituted enamino esters 77 and 79, unlike the enamino esters discussed in 
chapter 4, contain an amino acid R group at position 3, in this case the benzyl group of 
phenylanine. This particular R group is required for recognition by such target enzymes 
as chymotrypsin. 74' 75 Methodology largely developed by Seebach et al for the 
asymmetric synthesis of a,a-disubstituted amino acids,76 was used to allow the 
introduction of the benzyl group, with stereo-control, into enamino esters 77 and 79. 
Although (S)-phenylalanine was used here to allow the introduction of the benzyl group, 
extension of this work should allow the introduction of any amino acid R group at 
position 3. 
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Synthesis of benzoyl oxazolidinones 
Synthesis of 4-substituted oxazolidinone 65 
The syntheses of the oxazolidinone precursors to enamino esters 77 and 79 are 
summarized in Schemes 19 and 20. The key oxazolidinone 65 was prepared via the 
procedure reported by Seebach et a! (Scheme 19), 77 and involved the treatment of the 
Schiff base salt of (S)-phenylalanine, with benzoyl chloride (1 equivalent). The 
resulting mixture was stirred at -20° C, under nitrogen, for 12 h, and then at 4° C for 3 
days. An 1H NMR spectrum of the crude oxazolidinone product revealed there to be a 
single epimer which was assigned as the trans isomer (see later for cis/trans 
assignment). Purification by radial chromatography, and subsequent recrystallisation, 
gave the benzoyl oxazolidinone 65, as a white solid, in 33% yield. 
H2NXPh 
HO--( 'H 
0 
Scheme 19 
1. NaOH 
-2. PhCHO 
Synthesis of 4,4-disubstituted oxazolidinones 
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The sequence for the synthesis of 4,4-disubstituted benzoyl oxazolidinones is 
summarized in Scheme 20. The benzoyl oxazolidinone 65 was alkylated, with a high 
degree of specificity, using the method pioneered by Seebach.76 A solution of 
oxazolidinone 65, in THF, was cooled to -78° C, and treated with 1.2 equivalents of 
lithium hexamethyldisilazide (LiHMDS) in THF. The resulting solution was stirred at 
-78° C for 7 min. The alkylating agent, BrCH2C02tBu, was added and the solution was 
stirred at -78° C for 2 h, and then allowed to warm to 20° C over 16 h. An 1H NMR 
spectrum of the product again revealed a single epimer, the (2R, 4S)-epimer, and 
purification by radial chromatography, and subsequent recrystallisation, gave the tert-
butyl oxazolidinone 67, as a white solid, in 87% yield. 
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The alkylating agent used here, BrCH2C02tBu, differs from that previously used in 
reactions of this type. The tert-butyl ester of bromo acetic acid was used in preference to 
the benzhydryl ester61 since it allows easy hydrolysis to give the free acid 68. It has the 
added advantage of being readily available, requiring no prior preparation, and hence is 
the choice of alkylating agent in this case. 
The formation of the 4,4-disubstituted oxazolidinone 67, from oxazolidinone 65, 
proceeds via the unstable, planar enolate 66 (Scheme 20). The C4 stereogenic centre of 
the enolate controls the stereochemical outcome of the alkylation reaction. The 
alkylating group, in this case BrCH2C02tBu, approaches from the least sterically 
hindered face of the enolate, that is, opposite the C2-phenyl group. The configuration at 
C4 was initially dictated by the configuration of (S)-phenylalanine, and the overall 
stereochemical outcome of the alkylation process results in an inversion of 
configuration. Note that even though the benzyl group is inverted, an (S) assignment is 
still given in this case, due to priority of substituents about C4. Therefore, the amino 
acid stereo genic-centre controls the relative stereochemistry of the alkylation, and hence 
the absolute configuration of the final product. The assignment of configuration is 
discussed later (see Assignment of RIS Configuration to the Oxazolidinones). The use 
of a short reaction time, typically 7 min, between the addition of the base and the 
electrophile, minimizes the formation of self-addition by-products associated with 
reactions of this type. 78 
The Seebach alkylation reaction has been carried out with oxazolidinones derived 
from most amino acids, using a number of different alkylating agents and bases, and has 
proved to be a convenient method for the preparation of 4,4-disubstituted oxazolidinones 
of this type. 
The tert-butyl group of 67 was removed via treatment with a large excess of TF A, at 
oo C. Purification by extraction into aqueous NaHC03 resulted in emulsification, but 
eventually led to the isolation of the purified acid 68, as a white solid, in 41% yield. 
Attempts to increase this yield were carried out using the method described by S. Torii 
et a/.90 This involved the treatment of oxazolidinone 67 with HCl (0.5 equivalent), using 
phenol as a solvent. However, this gave the acid in only 19% yield and hence was not 
incorporated as a viable route for its preparation. 
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A solution of the acid 68 in dichloromethane was cooled to oo C and treated with 
oxalyl chloride (5 equivalents) and a catalytic amount ofDMF to give the corresponding 
acid chloride 69, in 100% yield. 
The benzoyl ~-keto ester oxazolidinone 71 (Scheme 20), was prepared from the 
treatment of the acid chloride 69 with meldrum' s acid (2,2-dimethyl-1 ,3-dioxane-4,6-
dione) and pyridine, in dichloromethane. The mixture was stirred at oo C for 50 min and 
then at 20° C for 45 min. The resulting acyl meldrum's intermediate was refluxed in 
ethanol for 4 hand the crude product was purified by radial chromatography to give the 
benzoyl ~-keto ester oxazolidinone 71, as an oil, in 73% yield. 
Attempts to synthesize the corresponding ~-keto amide 72 (Scheme 20) via reaction of 
the acyl meldrum's intermediate of 69, with glycine ethyl ester hydrochloride and 
triethylamine, proved unsuccessful. It was originally thought that further substitution, at 
C2; would sterically hinder the attack of the amine on the oxazolidinone ring, thereby 
allowing reaction at the alky 1 side chain of the mel drum's acid intermediate to give the 
desired ~-keto amide. However, this did not prove to be the case. Nevertheless, peptide 
chain extension is still possible via hydrolysis of the ethyl ester of 71 and the subsequent 
coupling of an amino acid, to give the desired ~-keto amide 72. 
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Assignment of R/S configuration to the 
oxazolidinones 
The benzoyl oxazolidinone 65 (Schemes 19 and 20), was assigned the trans 
configuration on the basis of the melting point, IR, 1H NMR, 13C NMR data which was 
identical to that reported in the literature. 82 
The original literature assignment of the trans configuration to 65 was based on the 
comparison of the chemical shifts of the protons at H2 and H4 with corresponding 
chemical shifts of cis and trans tert-butyl oxazolidinones 73 and 74. 77' 83 The H2 and 
H4 resonances are characteristically downfield in the trans isomer, relative to the 
corresponding cis isomer. 
Cis 
Compd 
R 73 oH2 oH4 
Me a 6.13 4.07 
CH2CH2SMe b 6.10 4.20 
75 - 4.92 
Ph 
F=o 
PhyN 
O~Ph 
0 
75 
Trans 
Compd ' 
74 oH2 oH4 
a 6.25 4.37 
b 6.21 4.52 
65 5.81 5.21 
The assignment of the trans configuration to 65 was also confirmed by the observance 
of a nuclear Overhauser enhancement (NOE) between H2 and CH2Ph.78 Therefore, 
having used (S)-phenylalanine as the starting material to fix the configuration at C4, this 
allowed the assignment of the absolute configuration of oxazolidinone 65 as the (2R, 4S) 
1somer 
The relative trans-configuration, of the 4,4-disubstituted benzoyl oxazolidinone 67 
was assigned on the basis of 1H NMR data and confirmed by single crystal x-ray 
structure analysis (Figure 20). This result also confirmed that the alkylation had 
occurred from the least sterically hindered face of the enolate 66 (Scheme 20). As the 
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absolute stereochemistry of the precursor oxazolidinone 65 was known, this again 
allowed assignment of the absolute configuration of the 4,4-disubstituted oxazolidinone 
67 as the (2R, 4S) isomer. 
C33> 
C34~ 
~' 
C35 
C14 
C44 
Figure 20 X-ray Molecular Structure of 67 with Crystallographic Numbering Scheme 
X-ray molecular structure of compound 67 
A perspective drawing of compound 67, with atom labeling, is shown in Figure 20. 
The C2 tert-butyl analogues of oxazolidinones of type 73 and 74 (previous page), have 
been shown to adopt a slight envelope conformation for the oxazolidinone ring, with C2 
out of the plane of the other four atoms of the ring. 84• 85 These reports also reveal 
pyramidalization of the amide N-atom and that the N-acyl carbonyl 0-atom md the 
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acetal substituent are in an s-cis-conformation.84 The pyramidalization is thought to 
contribute to the steric bias of the oxazolidinone ring towards an incoming electrophile 
in Seebach alkylations of the type shown in Scheme 20.84 The structure of compound 67 
is a product of C4 alkylation and has an essentially planar oxazolidinone ring, little or no 
pyramidalization of the amide N-atom, and does not have theN-acyl carbonyl 0-atom in 
an s-cis-position relative to the acetal C2-substituent (see Figure 20). It should also be 
noted that the C21-26 and C 11-16 aromatic rings are orthoginal to each other giving rise 
to the possibility of deshielding of protons associated with the C2-phenyl ring (see later). 
Structural assignment and NMR data of 
oxazolidinones 
The introduction of chirality, at C2 and C4, into oxazolidinones comprising the series 
~5-71, gives rise to the possibility of multiple signal splitting due to the diastereotopic 
nature of some protons. 1H NMR spectra for compounds 67 and 71 respectively, 
illustrate that AB quartets are seen for the diastereotopic protons associated with 
C4CH2Ph and the C4CH2 of the alkyl group, as well as for the COCH2CO of the f)-keto 
i 
ester oxazolidinone 71. 
mu 
,I, 
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It is also interesting to note the chemical shift of the doublet at o 5.55. This resonance 
corresponds to two equivalent aromatic protons, associated with the C2Ph, being 
deshielded by the aromatic ring of the C4CH2Ph. This deshielding effect causes an 
upfield shift of the resonance associated with these two protons. This was observed in 
the solid state conformation as determined by single crystal x-ray analysis which clearly 
showed the two phenyl rings orthogonal to each other in the solid state (Figure 20). 
Significant 1H and 13C NMR spectral data for oxazolidinones 65, 67, 68 and 71 is 
summarized in Table 5. 
Table 5 
1HNMRdata 
C4CH2PhAbq C4CH2RABq 
Compd om oHa oHb JAB Hz oHa oHb JAB Hz 
65 5.81 3.41 3.79 N/A 
67 6.49 3.35 3.98 13.6 3.11 3.95 17.8 
68 6.46 3.41 4.04 13.4 3.25 4.13 18.1 
71 6.49 3.34 3.96 13.5 3.39 4.39 19.0 
13CNMRdata 
Compd C2. C4 C4CH2Ph C4CH2R Ph CO C5 
65 91.3 57.8 34.9 N/A 169.3 171.2 
67 91.5 66.3 42.3 40.3 169.7 173.2 
68 91.7 66.1 42.3 38.5 170.2 173.1 
71 91.6 65.4 42.2 48.0 169.9 173.0 
Comparison of the 1H NMR data of literature oxazolidinones with those in Table 5 
showed that H2 characteristically resonated at o 5 .29-6.51. In the alkylated 
oxazolidinones 67, 68 and 71, C4CH2Ph and C4CH2R appeared as AB quartets with 
J::13Hz and J::18Hz, respectively. 13C NMR resonances for C2, C4, C5, C4CH2Ph, 
C4CH2R, and PhCO, appeared at characteristic chemical shifts for all examples. C2 
typically resonates at o 91 ppm for all examples, despite the downfield shift of H2 for the 
disubstituted oxazolidinone compounds 67, 68 and 71. 
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Synthesis of the target en amino esters 
The target enamino esters 77 and 79 were synthesized from benzoyl P-keto ester 
oxazolidinone 71 via the process developed by Hashiguchi et al (Scheme 21).60 
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Enamino esters 77 and 79 were prepared by refluxing a solution of the benzoyl P-keto 
ester oxazolidinone 71, in 1,2-dichloroethane, with methylamine (20 equivalents), or 
2,4-dimethoxybenzylamine hydrochloride (5 equivalents) and triethylamine (5 
equivalents). After 90 min, the solution was filtered and the solvent removed under 
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reduced pressure. The residue was then heated at 150° C, under reduced pressure (1 mm 
ofHg), for 1 h. Purification by radial chromatography gave 77, as a white solid, in 43% 
yield. Attempted purification of enamino ester 79, by radial chromatography, using 2:3 
ethyl acetate/petroleum ether as the elutant, gave a mixture of the desired product, as 
well as other unidentified material. Crystallization of this mixture using ethyl 
acetate/petroleum ether gave 79, as a tan solid, in 8% yield. 
The enamino esters 77 and 79 probably form via a mechanism analogous to that shown 
in Figure 15 (Chapter 4) for the preparation of 3-substituted enamino esters 59 and 61. 
It should be noted that in the preparation of 77 and 79, the corresponding imide 
products were not observed. This was proposed to be due to the increased substitution, 
at C4 and C2, of the acyclic oxazolidinone precursor 71. This represents an example of 
a general effect commonly known as the 'Thorpe-Ingold' or 'gem-dialkyl' effect. It has 
long been known in the literature that, for a given ring size, alkyl substituents on an 
acyclic system promote cyclization and favour the ring form in an equilibrium involving 
the opening and closing of a ring. To explain these observations, Thorpe and Ingold 
suggested that a decrease in the internal angle of a small ring, led to a spreading apart of 
the external angle.79 This, in turn, relieved steric interactions between substituents 
attached to the same carbon, thus favouring the ring form over the open chain form. 
Although this was shown to be true for five-membered rings such as 77 and 79, in 
1960 Allinger and Zalkow proposed a more general theory to account for this increased 
rate in ring formation. 81 This was termed the "gem-dialkyl effect" and was described in 
terms of the enthalpies and entropies of open-chain vs ring compounds. It was found 
that there were fewer extra gauche interactions in rings than there were in the 
corresponding open chains. This meant that, compared with an unsubstituted chain, the 
substituted chain (e.g. 71 Scheme 21) had a more favourable enthalpy ofring closure. In 
addition, there was an entropy effect, due to branching, based on the fact that branching 
reduced the rotational entropy of open- chain compounds, something that could not 
occur in the ring form due to its rigidity. Therefore, this increased entropy factor, where 
entropy is not lost, also favours ring closure for the more branched compounds. Since 
branching both reduces the enthalpy, and increases the entropy of ring closure, it 
therefore decreases the free energy of ring closure and leads to an equilibrium more 
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favourable to the ring structure.80 In the case ofthe formation of77 and 79 (Scheme 21), 
this effect adds to the stability of the form of the 3,3-disubstituted oxazolidinones , 
making them less susceptible to ring opening via attack by an amine. This results in 
imide formation (via mechanism B, Figure 18, Chapter 4) being suppressed, thereby 
favouring the formation of the enamino esters 77 and 79 (Scheme 21). This effect is not 
seen for the monosubstituted oxazolidinone 28, and the corresponding imide 62 was 
isolated (Figure 18). 
Structural assignment and NMR data of target 
enamino esters 
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Ph_llNH ,·-Ph 
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The configuration of the double bond of enamino esters 77 and 79 was assigned on the 
basis of 1H NMR spectroscopy. Both 77 and 79 were assigned as the (E) isomer on the 
basis of similar chemical shifts for the (H4)2 resonance, to those observed in earlier 
unsubstituted and 3-substituted enamino esters (see Chapter 4). This reflects the 
deshielding influence of the C02Et group on (H4)2 and the result was used to assign the 
EIZ configuration of simpler unsubstituted enamino esters discussed in chapter 4, 70 as 
well as compounds of this type described in the literature. It should also be noted that in 
all the N-acylated enamino esters and N-acylated enamino amines 4escribed here, theE 
isomer is invariably favoured. 
Key 13C NMR resonances of the enamino ester 77, were assigned following an NMR 
proton-carbon heteronuclear correlation experiment. The 1H-13C NMR correlation 
experiment showed that the 1H NMR resonance at 8 4.91 was coupled to the 13C NMR 
resonance at 8 91.8, characteristic of =CH. The 1H NMR resonance at 8 6.74 did not 
show coupling to any 13C NMR resonance and was hence assigned as NH. Comparison 
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of these resonances with those of the enamino ester 79, showed that NH was downfield 
from =CH for both compounds. 
The 1H NNIR. spectrum of enamino esters 77 and 79 were found to again display signal 
splitting due to the stereogenic centre at C3. The resonances for (H4)2 and OCH2CH3 
appear as an AB quartet and a multiplet respectively, while the resonance for CH2Ph 
appears as a narrow multiplet, upfield of that for (H4)z. The NCHz resonance for 
enamino ester 79 also appears as an AB quartet characteristic of the diastereotopic 
nature of these protons. Characteristic 1H and 13 C NIYIR data is summarized in Table 6 
with the 1H NNIR. spectra of both compounds shown below. 
Table 6 
lHNNIR. 
Compd =CH C4CHzPh OCHzCH1 NCHz NH 
77 4.91 t 3.12 m 4.09m N/A 6.74 
79 5.07 3.12 m 4.09 m 4.61 Abq 6.56 
J=16.1Hz 
13c NNIR 
Compd =CH C-+CHzPh C3 C4 C5 
77 91.8 42.8 59.5 36.5 156.4 
79 93.1 42.9 59.4 36.6 154.1 
0 
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Mass spectra of enamino esters 77 and 79, like that of oxazolidinones 65-71, displayed 
a characteristically large signal at M-91, corresponding to the M-CH2Ph fragment. 
Conclusion and future work 
A general Meldrum's acid method was used to synthesize the succinimide-based B-
keto ester 23, as well as the aspartic acid-derived B-keto ester 28, as precursors to the 
synthesis of cyclic enamino esters. This method was also used to prepare the' B-keto 
amide 24, which allowed chain extension in the C-direction in one easy step. The 
attempted synthesis of the corresponding aspartic acid-derived B-keto amide 29 was 
unsuccessful and this was proposed to be due to the susceptibility of the oxazolidinone 
. ring to attack by an amine. 
Compounds 23 and 24 were then used in the preparation of cyclic enamino esters 55, 
56, 59, 61, 63 and 64, via their reaction with an amine, with 59 and 61 being examples 
ofFreidinger lactams where the amide bond is locked in a cis-like conformation. 
The phenylalanine-derived 3,3-disubstituted enamino esters 77 and 79 were also 
synthesized to allow the incorporation of an amino acid R group (CH2Ph) at the 3-
position of the succinimde ring. These cis-amide bond mimics contained an N-alkylated 
amide bond (Me, D:Nffi), and have the same configuration as the natural peptide 
substrates. The key configuration at C3 of 77 and 79, was controlled by the 
configuration of the starting amino acid used in the syntheses. The configuration of 
these compounds was determined by 1H NMR and confirmed by the obtaining of a 
single crystal x-ray structure of 67, a key compound in the synthesis of enamino esters 
77 and 79. Peptidomimetics of this type can be incorporated into peptide sequences to 
mimic a cis-amide bond configuration. By studying the effect that this has on the 
activity of a corresponding enzyme or receptor, information can be gained as to the bio-
active conformation of a given peptide. 
The method of synthesizing the enamino esters has shown to be versatile and in the 
future could be adapted to incorporate the mimics into different peptides so that 
maximum interaction with the desired target is achieved. Also, different recognition 
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groups could be incorporated at the 3-position to allow other enzymes and receptors to 
be targeted. 
Use could be made of different forms of protected ammonia, other than 2,4-
dimethoxybenzylamine, in an effort to increase the overall yield, purity and ease of 
synthesis of compounds of this type. Further, methods for the hydrolysis of the ethyl 
ester and the reduction of the ene-lactam double bond of 77 and 79 need to be 
investigated, to allow chain extension in the C-direction and systems that more closely 
resemble the geometry of the natural substrate. Preliminary results indicate that this 
could be achieved via hydrogenation, although further investigation is still required. 
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General Experimental 
All solvents used throughout the work described in this thesis were freshly distilled 
prior to use, and petroleum ether applies to the fraction with boiling point 60-70° C. 
Flash chromatography was performed using 250-400 mesh grade 923 silica gel on 18-
20 em columns, under a positive air pressure. Thin layer chromatography was 
performed on plastic backed silica plates. Radial chromatography was performed on 
a Harrison and Harrison chromatotron using 2 mm silica plates. Melting points were 
measured using an Electrothermal melting point apparatus and are uncorrected. 
Proton NMR spectra were recorded on a Varian Unity 300 spectrometer in CDCb, 
using Me4Si as an internal reference, recorded as (multiplicity, coupling constants, 
number of protons, assignment). 13C NMR spectra were recorded on a Varian XL-
300 spectrometer referencing through CDCh. Infrared absorption spectra were 
recorded, using KBr plates, on a Shimadzu FTIR-8201 PC spectrometer. Mass 
spectroscopy results were obtained from a Kratos MS80RF A spectrometer. 
Preparation of 3-Carbomethoxypropionyl chloride 21 
MeO~Cl 
0 0 
A solution of succinic anhydride (28.430 g, 0.285 mol) in methanol (14 ml) was 
refluxed over a steam bath for 35 min. The mixture was removed from the steam 
bath and swirled frequently for 15 min until homogeneity resulted, and the solution 
was then heated on a steam bath for an additional 30 min. The methanol was 
evaporated to leave methyl hydrogen succinate 20, as a white crystalline solid (3 7.10 
g, 98.6%). mp 56-58° C (lit mp 57-58° C).89 
A solution of methyl hydrogen succinate 20 (20.191 g, 0.153 mol), and thionyl 
chloride (23 ml, 0.315 mol, 2.1 equiv), was warmed at 30-40° C for 3 h. The mixture 
was distilled under reduced pressure to give 3-carbomethoxypropionyl chloride 21 
(14.329 g, 62%). bp 58-65° Cat lmm Hg (lit bp 92-93° Cat 18 mm Hg).89 
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1 H NMR (CDCb) 8 2.68 (t, J=6.6Hz, 2H, CH2C02Me), 3.22 (t, J=6.6Hz, 2H, 
CH2COC1), 3.72(s, 3H, Me). 
Preparation of 1-Ethyl-6-methyl-3-oxohexandioate 23 
0 MeO~OEt 
0 0 
2,2-Dimethyl-1,3-dioxan-4,6-dione (Meldrum's acid) (1.970 g, 0.014 mol, 1.1 
equiv) was dissolved in dichloromethane (5 ml) and the solution was cooled to oo C. 
Dry pyridine (2.69 ml, 0.033 mol, 1.1 equiv) was added over 10 min, followed by 3-
carbomethoxypropionyl chloride 21 (1.645 ml, 0.013 mol, 1 equiv) over 90 min. 
After stirring at 0° C for 50 min, and at 20° C for 45 min, the mixture was poured into 
2N aqueous HCl (2 ml) containing crushed ice. The organic layer was removed and 
the aqueous layer was extracted with dichloromethane (2x0.5 ml). The combined 
dichloromethane extracts were washed successively with 2N HCl (2x0.5 ml), 
saturated aqueous NaCl (0.8 ml), dried (MgS04), and evaporated to give the acyl 
meldrum's acid intermediate 22, as a dark red solid (2.385 g), which was used in the 
next step without further purification. 
The acyl meldrum's acid intermediate 22 (2.385 g, 9.24 mmol), was refluxed in dry 
ethanol ( 40 ml) for 2.5 h to yield a red/brown oil. The oil was dissolved in 
dichloromethane and successively washed with cold saturated aqueous NaHC03 (10 
ml), water (1 0 ml), dried (MgS04), and evaporated to yield the P-keto ester 23 as an 
oil (2.205 g, 84%). 
1H NMR (CDCb) 8 1.24 (t, J=7.1Hz, 3H, CH2CH3), 2.58 (t, J=6.6Hz, 2H, 
CH2C02Me), 2.84 (t, J=6.6Hz, 2H, CH2CO), 3.46 (s, 2H, COCH2CO), 3.64 (s, 3H, 
OMe), 4.16 (q, J=7.1Hz, 2H, CH2CH3). 
13C NMR (CDCh) 8 13.57, 27.16, 36.88, 48.69, 51.24, 60.79, 166.53, 172.31, 200.73. 
IR(KBr) 1739,1720 cm-1. 
HRMS Found 202.0841 (Calcd for C9H140s 202.0841). 
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Preparation of (E)-5-Ethoxycarbonylmethylidene-1-methylpyrrolidin-2-one 55 
Method A 
0-J)JOEt 
I 
Me 
90 
To a solution of the ~-keto ester 23 (100 mg, 0.5 mmol, 1 equiv), in 1,2-
dichloroethane (10 ml), was added methylamine hydrochloride (300 mg, 4.5 mmol, 9 
equiv) and triethylamine (0.6 ml, 4.5 mmol, 9 equiv), and the mixture was refluxed, 
under nitrogen, for 90 min with azeotropic removal of water. The solution was 
filtered and the solvent was removed by rotary evaporation. The residue was then 
heated, at 150° C, at 1mm Hg for 1 h. Purification of the residue by radial 
chromatography using 1: 1 ether/petroleum ether gave the product 55 as a white solid 
(23 mg, 26%). mp 113-114° C (lit mp 118° C).73 
1H NMR (CDCh) o 1.28 (t, J=7.1Hz, 3H, CH2CH3), 2.55 (m, 2H, (H3)2), 2.99 (s, 3H, 
NMe), 3.23 (m, 2H, (H4)2), 4.15 (q, J=7.1Hz, 2H, CH2CH3), 5.18 (t, J=1.9Hz, 1H, 
=CH). 
13C NMR (CDCh) o 14.39 (CH2CH3), 24.53 (C3), 26.89 (NMe), 28.02 (C4), 59.52 
(CH2CH3), 91.65 (=CH), 160.59, 167.23, 176.79 (3xCO). 
IR (KBr) 1730, 1625 cm-1. 
HRMS Found 183.0895 (Calcd for C9H13N03 183.0895). 
MethodB 
To a solution of the ~-keto ester 23 (100 mg, 0.5 mmol, 1 equiv), in 1,2-
dichloroethane (10 ml), was added methylamine (1.6 ml of 6M solution in 1,2-
dichloroethane, 0.01 mol, 20 equiv) and the mixture was refluxed, under nitrogen, for 
90 min with azeotropic removal of water. The solvent was removed by rotary 
evaporation and the residue was heated at 150-160° Cat 1mm for 1 h. Purification 
by radial chromatography using 1:1 ether/petroleum ether gave 55 as a white solid 
(16 mg, 18%). mp 112-114° C 
NMR data as above. 
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Preparation of (.E)-1-(2.4-Dimethoxybenzyl-5-ethoxycarbonylmethylidenepyrrol-idin-
2-one 56 
O~OEt 
n MeO .& OMe 
To a solution of the ~-keto ester 23 (50 mg, 0.248 mmol, 1 equiv), in 1,2-
dichloroethane (5 ml), was added 2,4-dimethoxybenzylamine hydrochloride (51 mg, 
0.3 mmol, 1 equiv) and triethylamine (0.34 ml, 0.3 mmol, 1 equiv) and the mixture 
was refluxed, under nitrogen, for 45 min. The solvent was removed under reduced 
pressure and the residue heated at 150-160° Cat lmm Hg for 1 h. The resulting oil 
was purified by radial chromatography using 1:1 ethyl acetate/petroleum ether, and 
the main fraction was recrystallized to give the pyrrolidinone 56 (21 mg, 28%). mp 
112-113° c. 
1H NMR (CDCb) 8 1.24 (t, J=7.1Hz, Me), 2.63 (t, J=7.6Hz, 2H, (H4)z), 3.25 (t, 
J=7.6Hz, 2H, (H3)2), 3.79 and 3.86 (s, 2x3H, 2x0Me), 4.10 (q, J=7.0Hz, 2H, 
CHzCH3), 4.68 (s, 2H, NCH2Ar), 5.32 (s, lH, =CHCO), 6.43 (d, J=8.5Hz, lH, ArH, 
6.45 (s, lH, ArH), 6.95 (d, J=8.5Hz, lH, ArH). 
13C NMR (CDCb) 8 14.39 (CH2CH3), 24.59 (C3), 28.14 (C4), 38.32 and 55.34 
(2x0Me), 59.40 (CH2CH3), 92.63 (=CH), 98.44, 104.44, 115.27, 128.69, 157.85, 
159.31, 160.40, 167.48, 177.19. 
IR (KBr) 1735, 1618 cm-1 
HRMS Found 319.1420 (Calcd for C11H2tNOs 319.1420). 
Anal. Calcd for C11H21NOs: C, 63.94; H, 6.63; N, 4.39. Found: C, 63.96; H, 6.70; N, 
4.52. 
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Preparation of Methyl-5-CN-Ethoxycarbonylmethylcarbamoy 1)-4-oxo-pentanoate 24 
0 
MeoD----JLN ---co Et 
0 0 H 2 
Meldrum's acid (500 mg, 3.5mmol) was dissolved in dichloromethane (2 ml) and 
the solution was cooled to 0° C. Dry pyridine (0.68 ml, 3.5 mrnol) was added over 10 
min, followed by 3-carbomethoxypropionyl chloride 21 (0.42 ml, 3.3 mrnol) in 
dichloromethane (1 ml), over 60 min. The mixture was stirred at oo C for 50 min and 
at 20° C for 45 min. The resulting red/brown solution was poured into 2N aqueous 
HCl (2 ml) containing crushed ice. The organic layer was removed and the aqueous 
layer was extracted with dichloromethane (2 ml). The combined dichloromethane 
extracts were successively washed with 2N aqueous HCl (2x0.5 ml), saturated 
aqueous NaCl (1 ml), dried (MgS04) and evaporated to give the acyl meldrum's acid 
intermediate 22 (0.716g). 
A solution of the acyl rneldrurn's acid intermediate 22 (0.716 g, 2.8 rnmol), glycine 
ethyl ester hydrochloride (0.42 g, 3 mrnol) and triethylamine (.0.42ml, 3 rnmol) was 
refluxed, under nitrogen, in dry benzene (25 rnl) for 4 h. The solvent was evaporated 
under reduced pressure and the residue was purified by radial chromatography using 
5:3 petroleum ether/ethyl acetate, to give 24 as an oil (383 rng, 47%). 
1H NMR (CDCb) 8 1.29 (t, J=7.0Hz, 3H, CH2CH3), 2.63 (t, J=6.4Hz, 2H, 
CH2C02Me), 2.87 (t, J=6.4Hz, 2H, CH2CO), 3.54 (s, 2H, COCH2CO), 3.69 (s, 3H, 
OMe), 4.05 (d, J=5.6Hz, 2H, NCH2), 4.22 (q, J=7.0Hz, 2H, CH2CH3), 7.42 (br s, 1H, 
NH). 
13C NMR (CDCb) 8 13.53, 27.00, 37.39, 40.89, 48.22, 51.39, 61.00, 165.32, 175.45, 
203.74. 
IR(KBr) 3354, 1739 (br), 1674 crn·1• 
HRMS Found 259.1056 (Calcd for CnH11N06 259.1056). 
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Preparation of (E)-1 Methyl-5-(N-ethoxycarbonylmethylcarbamoyl)-methylidene-
pyrrolidin-2-one 63 
o£VN--co.,Et ~ H ~ 
Me 
To a solution of 24 (65 mg, 0.25 mmol, 1 equiv), dissolved in 1,2-dichloroethane 
(10 ml), was added methylamine (0.83 ml of 6M solution in 1,2-dichloroethane, 15 
mmol, 20 equiv), and the mixture was refluxed, under nitrogen, for 90 min with 
azeotropic removal of water. The solvent was removed by rotary evaporation and the 
residue heated at 150° C at 1mm Hg for 1 h. Purification by radial chromatography 
using 7:3 ethyl acetate/dichloromethane gave 63 as a white solid (22 mg, 25%). mp 
129-130° C. 
1 - 0 H NMR (CDCb) 8 1.28 (t, J=7.1Hz, 3H, CH2CH3), 2.53 (m, 2H, (H3)2), 2.98 (s, 3H, 
NMe), 3.28 (m, 2H, (H4)2), 4.07 (d, J=4.9Hz, 2H, NHCH2), 4.22 (q, J=7.1Hz, 2H, 
CH2CH3), 5.12 (t, J=1.7Hz, 1H, =CH, 5.81 (s, 1H, NH). 
13C NMR (CDCb) 8 14.14 (CH2CH3), 24.36 (C3), 26.85 (NMe), 28.17 (C4), 41.22 
(NHCH2), 61.53 (CH2CH3), 93.03 (=CH), 158.33 (CO), 166.63 (CS), 170.42 (CO), 
176.85 (C2). 
IR (KBr) 1738, 1665, 1605 cm-1. 
HRl\1S Found 240.1110 (Calcd for CuH16N204 240.1110). 
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Preparation of (E)-1-2, 4-(Dimethoxybenzyl)-5-[(N-ethoxycarbonylmethylcarba-
moyl)-methylidenepyrrolidin-2-one 64 
OnJN-COEt nH , 
MeO h- OMe 
To a solution of 24 (100 mg, 0.4 mmol, 1 equiv), dissolved in 1,2-dichloroethane 
(10 ml), was added 2,4-dimethoxybenzylamine hydrochloride (236 mg, 1.2 mmol, 3 
equiv) and triethylamine (161 !-!1, 1.2 mmol, 3 equiv), and the mixture was refluxed, 
under nitrogen, for 90 min with azeotropic removal of water. The solution was 
filtered and the solvent removed by rotary evaporation. The residue was then heated 
at 150° C at 1mm Hg for 1 h. Purification by radial chromatography using 1:100 
methanoVether gave 64, 95% pure by NNIR, as an oil (56 mg, 39%). 
1H NMR (CDCh) 8 1.26 (t, J=7.1Hz, 3H, CH2CH3), 2.60 (m, 2H, (H3)2), 3.30 (m, 
2H, (H4)2), 3.77 and 3.86 (s, 2x3H, 2x0Me), 3.99 (d, J=5.4Hz, 2H, NHCH2), 4.18 
(q, J=7.1Hz, 2H, CH2CH3), 4.65 (s, 2H, NCH2), 5.17 (t, J=l.9Hz, 1H, =CH), 5.67 (br 
s, 1H, NH), 6.39 (dd, 2.4 and 8.3Hz, 1H, ArH), 6.44 (d, J=2.4Hz, 1H, ArH), 6.87 (d, 
J=8.3Hz, 1H, ArH), 
13C NMR (CDCh) 8 14.08 (CH2CH3), 24.32 (C3), 28.21 (C4), 38.35 (NCH2), 41.13 
(NHCH2), 55.32 and 55.37 (2xOlVIe), 61.39 (CH2CH3), 94.00 (=CH), 98.48, 104.40, 
115.12, 128.14, 156.88, 157.67, 160.30, 166.78, 170.38, 177.17. 
IR(KBr) 3325, 1732, 1668, 1616 cm·1. 
HRMS Found 376.1634 (Cald for C19H2~206 376.1635). 
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Preparation of 4(S)-3-Benzyloxycarbonyl-5-oxo-oxazolidin-4-yl acetic acid 25 
A mixture ofN-Cbz-(S)-aspartic acid (3.15 g, 11.8 mmol), paraformaldehyde (0.708 g, 
23.5 mol) and PTSA (0.135 g, 0.7 mmol) was refluxed in benzene (90 ml) for 1 h with 
azeotropic removal of water. The resulting solution was washed successively with ethyl 
acetate (12 ml), 0.3 M aqueous K2C03 (10 ml), water (3x5 ml), dried (MgS04) and the 
solvent was evaporated to give 4(S)-3-benzyloxycarbonyl-5-oxo-4-oxozolidine-4-yl 
acetic acid 25 as a white solid (2.007 g, 61%). mp 86-88° C (lit mp 87-88.5° C).52 
1H NNIR (CDCh o 3.05-3.15 (br d, 1=18.1Hz, 1H, CHaCO), 3.25-3.35 (br s, 1H, 
CHbCO), 4.36 (br s, 1H, H4), 5.19 (m, 2H, PhCH2), 5.30 (br d, J=3.4Hz, 1H, (H2)a), 
5.55 (br s, 1H, (H2)b), 7.37 (m, 5H, ArH). 
13C NMR (CDCL3) o 34.1, 51.3, 68.1, 78.2, 128.3, 128.6, B5.o, 152.7, 171.5, 174.9, 
178.2. 
IR (KBr) 3500-2600, 3010, 1805, 1720 cm-1. 
[a]0 20=+125.7° (c=3.53 methanol). 
Preparation of 4(S)-3-Benzyloxycarbonyl-5-oxo-oxazolidin-4-yl ethanoyl chloride 26 
The acid 25 (1.75 g, 6.3 mmol) was dissolved in dichloromethane (40 ml) and the 
solution was cooled to 0° C. Freshly distilled oxalyl chloride (2.72 ml, 31.3 mmol, 5 
equiv) and a catalytic quantity of dimethylformarnide were added and the mixture was 
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stirred at 0° C for 2 h and at 20° C for 16 h. The solvent was removed under reduced 
pressure. Dichloromethane (2 ml) was added and then removed under reduced pressure. 
This was repeated twice more. Final traces of oxalyl chloride were removed at 1mm to 
give the acid chloride 26 as a brown oil (1.87 g, quant). This was used in subsequent 
steps without purification. 
1H NMR (CDCh) o 3.50-3.60 (br d, J =18.6Hz, 1 H, (H2)a), 3.80-3.95 (br s, 1 H_. 
(H2)b), 4.33 (br s, 1 H, H4), 5.19 (m, 2 H, PhCHz), 5.32 (br d, J =3.5Hz, 1 H, 
CHaCOCl), 5.50 (br s, 1 H, CHbCOCl), 7.37 (m, 5 H, PhH). 
[a]n20=+94° (dichloromethane). 
Preparation of 4(S)-Ethyl 4-(3-benzyloxycarbonyl-5-oxo-2-phenyl-1,3-oxazolidin-4-yl) 3-
oxobutanoate 28 
z (N 0 
oDJOEt 
0 0 
Meldrum's acid (51 mg, 0.35 mmol, 1 equiv) was dissolved in dichloromethane (2 ml) 
and the solution was cooled to 0° C under nitrogen. Dry pyridine (0.136 ml, 1.7 mmol) 
was added drop-wise over 5 min. 
The acid chloride 26 (100 mg, 0.32 mmol), dissolved in dichloromethane (2ml), was 
added drop-wise to the mixture over 10 min. The mixture was stirred at 0° C for 50 min 
and then at 20° C for 45 min. The resulting red/purple solution was poured into 2N 
aqueous HCl (2 ml) containing crushed ice. The organic layer was separated and the 
aqueous layer was extracted with dichloromethane (2 ml). The combined 
dichloromethane extracts were washed with 2N HCl (2 ml), followed by saturated 
aqueous NaCl (1 ml), and then dried over MgS04. The solvent was removed by rotary 
evaporation to give the meldrum's acid intermediate 27 (0.133 g, 98%). 
The meldrum's acid intermediate 27 (0.133 g) was re:fluxed in dry ethanol under a 
nitrogen atmosphere for 2.5 h. The solvent was removed under reduced pressure to give 
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a red/purple oil. Purification by radial chromatography using 4: 1 dichloromethane/ ethyl 
acetate gave 28 as a yellow oil (0.102 g, 87%). 
1H NMR (CDCh) o 1.28 (t, J=7.0Hz, 3H, CH2CH3), 3.00-3.18 (br d, J=18.3Hz, 1~ 
C4CHa), 3.28-3.40 (br s, 1H, C4CHb), 3.42 (s, 2H, COCH2CO), 4.24 (q, J=7.0Hz, 2H, 
CH2CH3), 4.36 (br s, 1~ H4), 5.19 (m, 2H, PhCH2), 5.30 (br d, J=3.5Hz, 1H, (H2)a), 
5.51 (br s, 1H, (H2)b), 7.37 (m, 5H, PhH). 
13C NMR (CDCh) o 13.88, 40.86, 46.04, 51.36, 61.82, 68.08, 78.36, 128.22, 128.57, 
128.62, 135.06, 152,73, 166.88, 170.85, 199.95. 
IR(KBr) 1801,1717 (br) cm-1. [a]D20=+100° (dichloromethane). 
Preparation of 3(S)-3-Benzyloxycarbonylamino-1-(2, 4-Dimethoxybenzyl)-succinimide 62 
z 
HN 
0~~0 
n MeO .& OMe 
A mixture of the 0 keto ester 28 (50 mg, 0.14 mmol, 1 equiv) and 2,4-
dimethoxybenzylamine hydrochloride (32 mg, 0.2 mmol, 1.1 equiv) and triethylamine (22 
~. 0.2 mmol, 1.1 equiv) in toluene (3 ml) was refluxed under a nitrogen atmosphere for 
3 5 min. The solvent was removed by rotary evaporation and the residue was heated at 
150-160° C under reduced pressure (20mm Hg) for 1 hr. The product was purified by 
radial chromatography using 1: 1 ethyl acetate/petroleum ether to give 62 as a yellow oil 
(44 mg, 77%). 
1H NMR (CDCh) o 2.80 (dd, 1=5.4 and 17.1Hz, 1H, (H4)a), 3.11 (dd, 1=9.7 and 
18.5Hz, 1 H, (H4)b), 3.78 and 3.79 (s, 2x3H, 2x0Me), 4.34 (m, 1H, H3), 4.68 (ABq, 
JAB=14.2Hz, 2 H, NCH2), 5.11 (ABq, JAB=6.5Hz, 2H, PhCH2), 5.44 (br s, 1H, NH), 
6.41 (m, 2H, ArH), 7.18 (d, J =9.3Hz, 1H, ArH), 7.35 (m, 5H, ArH). 
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13C NMR (CDCh) o 35.87 (C4), 37.75 (NCH2), 50.27 (C3), 55.30 and 55.38(2x0Me), 
67.36 (PhCH2), 98.46, 103.94 , 115.49, 128.15, 128.28, 128.33, 128.56, 130.12 
(Aromatic C's), 155.84, 158.16, 160.58, 173.76, 175.28. 
LRMS (M) Found 398.1 (Calcd for C21H22N206 398.1478). 
Preparation of 3 (S)-(E)-3-Benzyloxycarbonylamino-5-ethoxycarbonylmethyl-idene-1-
methylpyrrolidin-2-one 59 
z 
HN 
Ol)JOEt 
I 
Me 
A solution of~ keto ester 28 (21 mg, 0.06 mmol, 1 equiv), and methylamine (170!-ll of a 
7 .1M solution of methylamine in 1,2-dichloroethane, 1.2 mmol, 20 equiv), were refluxed 
in 1,2-dichloroethane (10 rnl) for 90min. The irnine/enarnine mixture was then heated at 
150° C at 1mm Hg for 1h. Purification by radial chromatography using 4:1 
dichloromethane/ethyl acetate gave 59, as an oil (14 mg, 70%). 
1H NMR (CDCh) o 1.28 (t, J=7.3Hz, 3H, CH2CH3), 2.97-3.10 (m, 4H, NMe and (H4)a), 
3.82 (dd, 1=18.7 and 9.3Hz, 1H, (H4)b), 4.18(q, J=7.3Hz, 2H, CH2CH3), 4.38 (m, 1H, 
H3), 5.12 (ABq, JAB=6.4Hz, 2H, PhCH2), 5.19 (s, 1H, =CH), 5.49 (d, J=5.4Hz, 1H, 
NH), 7.34 (br s, 5H, PhH). 
13C NMR (CDCh) o 14.37 (C~CH3), 27.37 (NMe), 32.69 (C4), 50.20 (C3), 59.74 
(CH2CH3), 67.26 (PhCH2), 93.03 (=CH), 128.14, 128.27, 128.53, 137.97 (Aromatic 
C's), 155.21, 156.44, 166.80, 173,97 (3xCO and C=). 
HRMS mlz (M+) 91.1, 137.0, 179.0, 224.1, 287.1, 332.1 
Found 332.1374 (Calcd for C11H2oN20s 332.1373). 
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Preparation of 3(S)-(E)-3-Benzyloxycarbonylamino-1-ethoxycarbonylmethyl-5-ethoxy-
carbonylmethylidenepyrrolidin-2-one 61 
Glycine ethyl ester hydrochloride (73 mg, 0.53 mmol, 3 equiv) and triethylamine (73 ~1, 
0.53 mmol, 3 equiv) were added to l3 keto ester 28 (61 mg, 0.18 mol, 1 equiv), dissolved 
in benzene (1 0 ml), and the mixture refluxed, with azeotropic removal of water, for 
90min. The mixture was filtered and the solvent removed by rotary evaporation. The 
residue was then heated at 150° C, at lmm, for 1 h. Purification by radial 
chromatography using a lmm silica gel chromatotron plate, eluting with 4:1 
dichloromethane/ethyl acetate gave the enamino ester 61 as an oil. (44mg, 63%). 
1H NMR (CDCh) o 1.29 (t, J=7.1Hz, 6H, 2xCH2CH3), 3.11 (dd, J=4.9 and 18.5Hz, lH, 
(H4)a), 3.91 (dd, J=9.4 and 19Hz, (H4)b), 4.11-4.24 (m, 6H, 2 x CH2CH3 and NCH2), 
4.43 (m, lH, H3), 5.12 ( rn, 3 H, PhCH2 and =CH), 5.39 (br s, 1 H, NH), 7.35 (m, 5 H, 
ArB). 
13C NJviR (CDCh) o 14.07, 14.36, 32.85, 42.11, 50.06, 59.92, 62.12, 67.39, 93.50, 
128.19, 128.33, 128.58, 128.64, 154.84, 155.78, 166.27, 166.49, 173.74. 
FTIR (KBr) 3350, 1801, 1714, 1632, 1530 cm-1. 
HRMS (M) Found 404.1577 (Calcd for C2olhiN201 404.1583). 
THr: UORAHY 
UNIVERSITY OF CIINTEHBURY 
CHRISTCHURCH, f~.z. 
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Preparation of (2R, 4$)-3-Benzoyl-4-benzyl-2-phenyl-1,3-oxazolidin-5-one 65 
Ph 
Ph, f=o 
''(Ny-Ph 
0\\ ',H 
0 
100 
(S)-Phenylalanine (5 g, 30 mmol) was treated with 1M aqueous NaOH (30 ml, 30 
mmol) to give the corresponding Schiff base salt. A solution of the Schiff base salt, in 
1,2-dichloroethane (60 ml), was treated with benzaldehyde (5 ml, 45 mmol, 1.5 equiv) 
and the solution was refluxed, with azeotropic removal of water, for 24 h. The mixture 
was cooled to -20° C under nitrogen and benzyl chloroformate (2.1 ml, 12.2 mmol) was 
added. The mixture was stirred at -20° C for 12 h and then at 4°C for 3 days. The 
solvent was removed under reduced pressure and the residue partitioned between ethyl 
acetate (60 ml) and 5% aqueous NaHC03 (50 ml). The organic layer was extracted, 
washed successively with 5% aqueous KHS04 (50ml) and water (50 ml), dried (Na2S04), 
and evaporated to yield an oil. Purification by radial chromatography using 10:3 
petroleum ether/ethyl acetate gave the anti-oxazolidinone 65, as a white solid (3.479g, 
33%). mp 186-187° C (lit mp 184.3° C).82 
1H NMR (CDCh) 8 3.41 (br s, 1H, CHaPh), 3.79 (br s, 1H, CHJlh), 5.21 (s, 1H, H4), 
5.81 (s, 1H, H2), 7.06-7.41 (m, 15H, PhH). 
13C NMR (CDCh) 8 34.89, 57.76, 91.25, 126.64, 127.72, 128.52, 128.85, 129.88, 
130.82, 135.22, 136.13, 169.22, 171.23. 
[a]0 20=+302° (c=l.O, chloroform). 
HRMS (M) Found 357.1365 (Calcd for C23H19N03 357.1365). 
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Preparation of (2R, 4S)-tert-Butyl 3-Benzoyl-4-benzyl-5-oxo-2-phenyl-1 ,3-oxazol-idin-4-
yl ethanoate 67 
The oxozolidinone 65 (200 mg, 0.56 mmol, 1 equiv) was dissolved in THF (20 rnl) and 
the solution was cooled to -78° C. LiHMDS (0.68 rnl, 0.68 mmol, 1.2 equiv) was added 
and the resulting yellow solution was stirred at -78° C for 7min. 
Tert-Butyl-bromoacetate (0.1 rnl, 0.62 mmol, 1.1 equiv) was added and the solution 
was stirred at -78° C for 2h and was then allowed to warm to 20° C over 16h. The 
solution was partitioned between saturated N&Cl solution (15 ml) and ether (10 rnl). 
The aqueous layer was separated and extracted with ether (1 0 rnl). The combined ether 
extracts were washed with water (2x5 rnl), dried (Na2S04) and evaporated to give 67 as a 
pale yellow solid (217 mg, 87% ). mp 180-181 o C. 
1H NMR (CDCb) o 1.54 (s, 9H, tBu), 3.11 and 3.95 (ABq, JAB=17.8Hz, 2H, CH2C02), 
3.35 and 3.98 (ABq, JAB=13.6Hz, 2H, C4CH2Ph), 5.55(d, J=7.8Hz, 2H, ArH), 6.49 (s, 
IH, H2), 6.67 (t, J=7.8Hz, 2H, PhH), 6.82 (d, J=7.4Hz, 2H, PhH), 6.95 (t, J=7.6Hz, 
IH, PhH), 7.06 (t, J=7.4Hz, 2H, PhH), 7.17 (t, J=7.4Hz, 1H, PhH), 7.41 (m, 5H, PhH). 
13C NMR (CDCh) o 28.04 (C(CH3)3), 40.27 (CH2C02tBu), 42.26 (CH2Ph), 66.28 (C4), 
82.20 (C(CH3) 3), 91.54 (C2), 125.26, 127.68, 127.74, 127.89, 128.18, 128.90, 128.09, 
129.33, 130.89, 134.61, 135.30, 136.58, 169.71 (PhCO), 170.07 (C02tBu), 173.18 
(C5). 
IR (K.Br) 1791.7, 1720.4, 1654.8 cm-1. 
HRMS (M) Found 471.2053 (Calcd for C2A~05 471.2047) 
Anal. Calcd for C29H29NOs: C 73.87; H 6.20; N 2.97. Found: C 74.07; H 6.24; N 2.85. 
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Preparation of (2R, 4S)-tert-Butyl 3-Benzoyl-4-benzyl-5-oxo-2-phenyl-1,3-oxazol-idin-4-
yl acetic acid 68 
Method A. 
Tert-Butyl oxazolidinone 67 ( 500 mg, 1.1 mmol, 1 equiv) was dissolved in 
dichloromethane (5 ml) and cooled to 0° C. TFA (13.7 ml, 0.18 mol, 168 equiv) was 
added and the solution was stirred at 0° C for 5 min. The solution was then diluted with 
dichloromethane (1 ml), washed with water (3x11.5 ml) and extracted with 5% aqueous 
NaHC03 solution (2x10 ml). The NaHC03 extracts were combined, cooled to 0° C, 
acidified to pH 1-3 with lN HCl and extracted with ethyl acetate (3x15 ml). The 
combined ethyl acetate extracts were dried (Na2S04) and the solvent evaporated to yield 
oxazolidinone 68 as a white solid (179 mg, 41 %). mp 207-210° C. (lit mp 207.5-211° 
C).78 
1H NMR (CDCh) o 3.25 and 4.13 (ABq, JAB=l8.1Hz, 2H, CB2C02H), 3.41 and 4.04 
(ABq, JAB=13.4Hz, 2H, CH2Ph), 5.54 (d, J=7.4Hz, 2H, PhH), 6.46 (s, 1H, H2), 6.68 (t, 
J=7.8Hz, 2H, PhH), 6.83 (d, J=7.3Hz, 2H, PhH), 6.96 (t, J=7.5Hz, 1H, PhH), 7.07 (t, 
J=7.5Hz, 2H, PhH), 7.18 (t, J=7.5Hz, 1H, PhH), 7.42 (m, 5H, PhH). 
13C NMR (CDCh) o 38.53 (CH2C02H), 42.33 (CH2Ph), 66.09 (C4), 91.70 (C2), 
125.29, 127.79, 127.89, 127.96, 128.32, 129.09, 129.26, 129.57, 130.92, 134.28, 
135.00, 136.12, 170.21 (PhCO), 172.85 (C02H), 173.13 (C5). 
IR(.KBr) 1797, 1726,1612,1595 cm-1. 
[a]n20 = +64° (c 0.9; dichloromethane). 
HRMS (M+l) Found 416.1498 (Calcd for C25H21N05 415.1421). 
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Method B. 
A mixture of tert-Butyl oxazolidinone 67 (100 mg, 0.21 mmol, 1 equiv) and phenol 
(400 mg, 4.2 mmol, 20 equiv) was heated to 45°C. When the phenol had melted, 
aqueous HCl (53 ~L of 2N solution, 0.1 mmol, 0.5 equiv) was added and the mixture 
was stirred at 45° C for 3 h. The mixture was then diluted with ethyl acetate (10 ml) and 
extracted with saturated aqueous NaHC03 (5 ml). The aqueous extract was cooled in an 
ice bath, acidified to pH 1 with 10% aqueous HCl and extracted with ethyl acetate (2x5 
ml). The combined ethyl acetate extracts were dried over MgS04 and the solvent was 
removed under reduced pressure to give the product 68 as a white solid (16mg, 19%). 
mp 208-210° C 
NMR data as above. 
Preparation of (2R, 4S)-3-Benzoyl-4-benzyl-5-oxo-2-phenyl-1 ,3-oxazolidin-4-yl ethanoyl 
chloride 69 
Ph 
'f=o 
Ph,, N -Ph 
'( ,, 0~COC1 
0 
The acid 68 (240 mg, 0.58 mmol, 1 equiv) was dissolved in dichloromethane (10 ml) 
and the solution was cooled to 0° C. Freshly distilled oxalyl chloride (0.28 ml, 2.9 mmol, 
5 equiv) and a catalytic quantity ofDMF were added. The mixture was stirred at 0° C 
·for 2h and at 20° C for 16h. The solvent was removed by rotary evaporation and more 
dichloromethane (2 ml) was added. This was repeated 3 times. Final traces of oxalyl 
chloride were removed at 1mm to yield the acid chloride 69 as a solid (262mg, quant), 
which was used in subsequent steps without further purification. 
1H NMR (CDCh) 8 3.38 and 3.97 (ABq., JAB=13.2Hz, 2H, CH2Ph), 3.74 and 4.64 (ABq, 
JAB=19.2Hz, 2H, CH2COCl), 5.51 (dd, J=7.3Hz, 2H, PhH), 6.37 (s, 1H, H2), 6.68 (m, 
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2H, PhH), 6.80 (m, 2H, PhH), 6.96 (m, 1H, PhH), 7.08 (m, 2H, PhH), 7.17 (m, 2H, 
PhH), 7.35-7.46 (m, 5H, PhH). 
Preparation of (2R 4S) Ethyl 4-(3-Benzoyl-4-benzyl-5-oxo-2-phenyl-1,3-oxazol-idin-4-
yl) 3-oxobutanoate 71 
Meldrum's acid (96 mg, 0.67 mmol, 1.1 equiv) was dissolved in dichloromethane (2 
ml) and the solution cooled to 0° C under nitrogen. Dry pyridine (154 11L, I. 51 mmol, 
2.5 equiv) was added drop-wise over 5 min followed by a solution of the acid chloride 69 
(262 mg, 0.61 mmol, 1 equiv) dissolved in dichloromethane (2 ml) which was added 
drop-wise over 10 min. The mixture was then stirred at 0° C for 50 min and at 20° C for 
45 min. The resulting solution was poured into aqueous 2N HCl (2 ml) containing 
crushed ice. The organic layer was removed and the aqueous layer was extracted with 
dichloromethane (2 ml). The combined dichloromethane extracts were washed 
successively with aqueous 2N HCl (1 ml), saturated aqueous NaCl (1 ml) and dried over 
MgS04. The solvent was removed by rotary evaporation to give the acyl meldrum' s 
compound 70. 
Acyl meldrum's compound 70 (315 mg, 0.57 mmol) was refluxed under a nitrogen 
atmosphere in dry ethanol for 2. 5h. Purification by radial chromatography using 3 :7 ethyl 
acetate/petroleum ether gave the~ keto ester 71 as a yellow oil (203 mg, 73%). 
1H NMR{CDCh) o 1.26 (t .. J=7.3Hz .. 3H> CH2CH.1}, 3.34 and 3.96 (ABq .• JAB=l3.5Hz_, 
2H, C4CH2Ph), 3.39 and 4.39 (ABg, JAB=19.0Hz, 2H, C4CH2CO), 3.59 (ABg, 
JAB-=-\~ .1Jm, 'lB., 'Cliz'C'02nt), 4 .'l'l \ tJ., J=.l :Yih, 'lB., 'Cliz'Clh), 5.54 \ u, J=.l.3fu, 'lB., 
PhH), 6.49 (s, 1H, H2), 6.68 (m, 2H, PhH), 6.78 (m, 2H, PhH), 6.96 (m, 1H, PhH), 
7.05 (m, 2H, PhH), 7.17 (m, 1H, PhH), 7.38-7.44 (m, 5H, PhH). 
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-'C NMR (CDCh) o 14.03, 42.23, 48.02, 49.04, 61.87, 65.36, 91.61, 125.32, 127.74, 
127.90, 127.95, 128.22, 129.00, 129.21, 129.39, 130.91, 134.45, 135.02, 136.30, 
166.12, 169.91, 172.98, 201.30. 
IR 1794. 1743_, 171~. 1651 cm-1. 
HRMS (FAB) (M+1) Found 486.1917 (Calcd for Cz9HzsN06 486.1917). 
Preparation of 3(S)-(E)-3-Benzoylamino-3-benzyl-5-ethoxycarbonylmethylidene-1-
methylpyrrolidin-2-one 77 
0 )l 
Ph NH ,,-ph 
hJ 0 N :c--.. OEt 
I 
Me 
To a solution of ~-keto ester 71 (50 mg, 0.1 mmol, 1 equiv) in 1,2-dichloroethane (10 
ml) was added methylamine (340 !J.L of 6M solution in 1 ,2-dichloroethane, 2 mmol, 20 
equiv) and the mixture refluxed under nitrogen for 90 min. The solvent was removed by 
rotary evaporation and the residue heated at 150° C at 1mm for 1 h. Purification by 
radial chromatography using 9:1 dichloromethane/ethyl acetate gave the product 77 as a 
white solid (17mg, 43%). mp 231-232° C. 
1H NMR (CDCh) o 1.23 (t, 1=7.3Hz, 3H, CH2CH3), 2.87 (s, 3H, NMe), 3.12 (m, 2H, 
PhCH2), 3.39 (dd, 1=18.8 and 2.0Hz, 1H, (H4)a), 3.81 (dd, 1=20.5 and l.OHz, 1H, 
(H4)b), 4.09 (m, 2H, CH2CH3), 4.91 (br t, 1=1.5Hz, 1H, =CH), 6.74 (s, 1H, NH), 7.16-
7.26 (m, SH, PhH), 7.38(m, 2H, PhH), 7.46 (m, 1H, PhH), 7.70 (dd, 1=6.9 and 1.5Hz, 
2H, PhH). 
13C NMR (CDCh) o 14.37 (CHzCH3), 27.1Z (NMe), 36.53 (C4), 42.81 (CH2Ph), 59.46 
(C3), 59.73 (CH2CH3), 91.81 (=CH), 127.01, 127.84, 128.57, 128.63, 129.94, 131.99, 
133.09, 133.20, 156.37 (C5), 166.63, 166.82, 175.76 (3xCO). 
IR (KBr) 1736, 1692, 1655, 1618 cm-1. 
FIRMS Found 392.1736 (Calcd for C23H2..Nz04 392.1737). 
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Preparation of 3 (S)-(E)-Benzoylamino-3 -benzyl-5-ethoxycarbonylmethylidene-1-2, 4-
dimethoxybenzylamino-pyrrolidin-2-one 7 9 
0 
Pl~NH ,,--Ph 
r0 
0 ~OEt 
MeO h OMe 
To a solution of p keto ester 71 (75 mg, 0.15 mmol, 1 equiv) dissolved in 1,2-
dichloroethane (10 rnl) was added 2,4-dimethoxybenzylamine hydrochloride (157 mg, 
0.75 mmol, 5 equiv) and triethylamine (107 11L, 0.75 mmol, 5 equiv) and the mixture was 
refluxed for 90 min. The mixture was filtered and the solvent removed by rotary 
evaporation. The resulting residue was heated at 150°C at 1mm for lh. Purification by 
radial chromatography using 2:3 ethyl acetate/petroleum ether gave a mixture of product 
79 and other unidentifiable material. Crystallization from ethyl acetate/petroleum ether 
gave 79, as a tan solid (6mg, 8%). 
1H NMR (CDCh) i5 1.21 (t, J=7.1Hz, 3H, CH2CH3), 3.18 (s, 2H, PhCH2), 3.48 (dd, 
1=18.5 and 2.5Hz, 1H, (H4)a), 3.78 and 3.81 (s, 6H, 2x0Me), 3.88 (dd, 18.5 and 2.5Hz, 
lH, (H4)b), 4.07 (m, 2H, CH2CH3), 4.61 (ABq, JAB=16.1Hz, 2H, NCH2), 5.08 (br t, 
J=1.5Hz, 1H, =CH), 6.42 (m, 2H, ArH), 6.58 (s, lH, NH), 6.93 (d, J=9.3Hz, 1H, ArH), 
7.26-7.32 (m, 5H, PhH), 7.41 (m, 2H, PhH), 7.50 (m, 1H, PhH), 7.72 (dd, 1=8.3 and 
1.5Hz, 2H, PhH). 
Selected 13C NMR data i5 14.39 (CH2CH3), 36.62 (C4), 39.13 (NCH2), 42.88 (CH2Ph), 
55.29 (2x0Me), 59.42 (C3), 59.58 (CH2CH3), 93.14 (=CH), 98.30, 104.44, 114.87, 
121.91, 154.13 (CS). 
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Crystallographic Data for compound 67 
Table 1. Crystal data and structure refinement. 
Crystal data 
Em peri cal Formula 
Formula weight 
Crystal description 
Crystal colour 
Crystal system 
Space group 
Unit cell dimensions 
F(OOO) 
Volume 
z 
Density (calculated) 
Radiation 
Linear absorption coefficient 
Temperature of measurement 
Data collection 
Diffractometer 
Temperature of data collection 
Diffraction measurement method 
Absorption correction 
Reflections collected 
Independent reflections 
e range for data collection 
Range ofh, k, 1 
C29H29NOs 
471.53 
Block 
Transparent 
Orthorhombic 
P212121 
a= 9.7037 (2) A a= 90° 
b = 21.5236 (6) A ~ = 90° 
c = 11.9756 (3) A y = 90° 
1000 
2501.21 (11) A 
4 
1.252 Mg/m3 
MoK\a 'A= 0.71073 A 
Fine-focus sealed tube, graphite monochromator 
0.085 mrn-1 
293 (2) 
Siemens P4 
293 (2) K 
\w scans 
none 
11635 
3555 (Rint = 0.0702) 
1.89° to 23.31 o 
-10 s h s 4,-22 s k s 23,-12 s 1 s 13 
Appendix 
Refinement 
Refinement method 
Data/restraints/parameters 
Goodness-to-fit on F2 
Final R indices [I> 28 (I)] 
R indices (all data) 
Absolute structure parameter 
Largest diff. Peak and hole 
Extinction method 
Computer processing 
Data collection 
Data reduction 
Cell refinement 
Structure solution 
Structure refinement 
Graphics by 
Computer publication 
Full-matrix least-squares on F2 
3555/0/319 
1.086 
R1 = 0.0389, wR2 = 0.0869 
R1 = 0.0411, wR2 =0.0883 
1.1 (10) 
0.127 and -0.166eA-3 
none 
Siemens XSCANS 
Siemens SHELXTL 
Siemens XSCANS 
SHELXS-86 (Sheldrick 1990) 
SHELXS-93 (Sheldrick 1993) 
Siemens SHELXTL 
Siemens SHELXTL 
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Ofthe 11635 reflections obtained, 3555 were unique ( Rint = 0.0702) and were used in 
the full-matrix least-squares refinement [ SHELXL-93 (Sheldrick, 1993) ]86• The 
structure was solved by direct methods [ SHELXS-86 (Sheldrick, 1990) ]87 • Hydrogens 
were fixed in idealized positions. All non-hydrogen atoms were refined with anisotropic 
atomic displacement parameters. Neutral scattereing factors and anomolous dispersion 
corrections for non-hydrogen atoms were taken from Ibers and Hamilton88 • 
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Table 2. Atomic coordinates [ x 104 ] and equivalent isotropic displacement parameters 
[ A2 x 103 ] for l.U (eq) is defined as one third of the trace of the orthoginalized Uu 
tensor. 
X y z U (eq) 
N -1881 (2) -1076 (1) 3302 (1) 23 (1) 
01 -425 (1) -1789(1) 2510 (1) 28 (1) 
02 47 (2) -1322 (1) 890 (1) 37 (1) 
C2 -1103 (2) -1653 (1) 3554 (2) 24 (1) 
03 -3323 (2) -264 (1) 3800 (1) 38 (1) 
C4 -1480 (2) -810 (1) 2216 (2) 26 (1) 
04 1103 (1) -686 (1) 3371 (1) 39 (1) 
05 917 (1) 364 (1) 3331 (1) 31 (1) 
C5 -525 (2) -1316(1) 1776 (2) 27 (1) 
C6 -2663 (2) -754(1) 4048 (2) 26 (1) 
C7 -2832 (2) -1025 (1) 5194 (2) 27 (1) 
C8 -1796 (2) -974 (1) 5993 (2) 32 (1) 
C9 -2017 (2) -1198(1) 7065 (2) 40 (1) 
C10 -3262 (3) -1476 (1) 7333 (2) 43 (1) 
C11 -4282 (2) -1523 (1) 6549 (2) 43 (1) 
C13 -1924 (2) -2217 (1) 3893 (2) 25 (1) 
C14 -1701 (2) -2490 (1) 4932 (2) 30 (1) 
C15 -2368 (2) -3037 (1) 5213 (2) 33 (1) 
C16 -3239 (2) -3319(1) 4461 (2) 33 (1) 
C17 -3484 (2) -3047 (1) 3432 (2) 34 (1) 
C18 -2822 (2) -2498 (1) 3155(2) 29 (1) 
C19 -2709 (2) -715 (1) 1401 (2) 29 (1) 
C20 -363 (2) -1273 (1) 1243 (2) 26 (1) 
C21 -4816 (2) -1351 (1) 1874 (2) 36 (1) 
C22 -5644 (2) -1876 (1) 1726 (2) 47 (1) 
C23 -5280 (3) -2321 (1) 957 (2) 46 (1) 
C24 -4118 (2) -2249 (1) 312 (2) 40 (1) 
C25 -3306 (2) -1726 (1) 458 (2) 31 (1) 
C26 -703 (2) -193 (1) 2314 (2) 29 (1) 
C27 536 (2) -213 (1) 3068 (2) 28 (1) 
C28 2162 (2) 497 (1) 4016 (2) 33 (1) 
C29 3428 (2) 291 (1) 3382 (2) 49 (1) 
C30 2088 (2) 1199 (1) 4121 (2) 40 (1) 
C31 2036 (3) 195 (1) 5153 (2) 50 (1) 
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Table 3. Selected bond lengths [A] and angles [0 ]. 
N-C6 1.362 (2) N-C4 1.473 (2) 
N-C2 1,485 (2) 01-C5 1.349 (2) 
01-C2 1.442 (2) 02-C5 1.197 (2) 
C2-C13 1.508 (3) 03-C6 1.223 (2) 
C4-C5 1.524 (3) C4-C26 1.533 (3) 
C4-C19 1.554 (3) 04-c27 1.212 (2) 
05-C27 1.332 (2) 05-C28 1.488 (2) 
C6-C7 1.500 (3) C7-C12 1.388 (3) 
C7-C8 1.392 (3) C8-C9 1.388 (3) 
C9-C10 1.386 (3) C10-Cll 1.368 (3) 
C11-Cl2 1.381 (3) C13-C18 1.380 (3) 
C13-C14 1.392 (3) C14-C15 1.386 (3) 
C15-C16 1.376 (3) C16-C17 1.385 (3) 
C17-C18 1.386 (3) C19-C20 1.510 (3) 
C20-C21 1.386 (3) C20-C25 1.392 (3) 
C21-C22 1.398 (3) C22-C23 !.375 (4) 
C23-C24 1.376 (3) C24-C25 1.384 (3) 
C26-C27 1.504 (3) C28-C29 1.510 (3) 
C28-C31 1.514 (3) C28-C30 1.517 (3) 
C6-N-C4 121.9 (2) C6-N-C2 125.2 (2) 
C4-N-C2 111.71 (14) C5-01-C2 112.27 (14) 
01-C2-N 103.03 (14) 01-C2-C13 108.2 (2) 
N-C2-C13 117.35 (14) N-C4-C5 100.85 (14) 
N-C4-C26 113.5 (2) C5-C4-C26 110.3 (2) 
N-C4-C19 113.8 (2) C5-C4-C19 110.1(2) 
C26-C4-C19 108.1 (2) C27-05-C28 122.4 (2) 
02-C5-01 122.5 (2) 02-C5-C4 126.5 (2) 
01-C5-C4 111.0(2) 03-C6-N 121.8 (2) 
03-C6-C7 120.6 (2) N-C6-C7 117.6 (2) 
C12-C7-C8 119.4 (2) C12-C7-C6 119.2 (2) 
C8-C7-C6 121.3 (2) C9-C8-C7 119.8 (2) 
C10-C9-C8 119.9 (2) C11-C10-C9 120.3 (2) 
C10-C11-Cl2 120.3 (2) C11-C12-C7 120.3 (2) 
C 18-C 13-C 14 119.1 (2) C18-C13-C2 120.8 (2) 
C14-C13-C2 119.8 (2) C15-C14-C13 120.1 (2) 
C 16-C 15-C 14 120.2 (2) C15-C16-C17 120.1 (2) 
C16-C17-C18 119.7 (2) C13-C18-C17 120.8 (2) 
C20-C19-C4 115.4 (2) C21-C20-C25 118.2(2) 
C21-C20-C 19 121.3 (2) C25-C20-C19 120.5 (2) 
C20-C21-C22 120.3 (2) C23-C22-C21 120.1 (2) 
C22-C23-C24. 120.5 (2) C23-C24-C25 119.2 (2) 
C24-C25-C20 121.7 (2) C27-C26-C4 114.5 (2) 
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04-C27-05 
05-C27-C26 
05-C28-C31 
05-C28-C30 
C31-C28-C30 
125.8 (2) 
109.7 (2) 
110.4(2) 
101.5 (2) 
110.4 (2) 
04-C27-C26 
05-C28-C29 
C29-C28-C31 
C29-C28-C30 
Symmetry transformations used to generate equivalent atoms: 
124.5 (2) 
109.0 (2) 
113.1 (2) 
111.8 (2) 
112 
Table 4 Anisotropic displacement parameters [ A2 x 103 ]. The anisotropic displacement 
factor exponent takes the form: -2n2 [ (ha*i U11 + ... + 2hka*b*U12] 
Ull U22 U33 U23 U13 U12 
N 24 (1) 21 (1) 24 (1) 1 (1) -2 (1) 1 (1) 
01 29 (1) 22 (1) 33 (1) 1 (1) 6 (1) 2 (1) 
02 38 (1) 37 (1) 35 (1) -1 (1) 12 (1) 3 (1) 
C2 25 (1) 22 (1) 27 (1) -1 (1) 0 (1) 4 (1) 
03 44 (1) 30 (1) 41 (1) 2 (1) 4 (1) 13 (1) 
C4 29 (1) 21 (1) 27 (1) 2 (1) 0 (1) -1 (1) 
04 35 (1) 26 (1) 58 (1) 4 (1) -11 (1) -2 (1) 
05 30 (1) 24 (1) 39(1) -2 (1) -7 (1) -4 (1) 
C5 26 (1) 25 (1) 32 (1) 0 (1) -1 (1) -5 (1) 
C6 24 (1) 22 (1) 33 (1) -4 (1) -2 (1) 1 (1) 
C7 30 (1) 20 (1) 30 (1) -6 (1) 3 (1) 2 (1) 
C8 31 (1) 31 (1) 35 (1) -7 (1) 1 (1) 4 (1) 
C9 49 (1) 40 (1) 32 (1) -6 (1) -5 (1) 13 (1) 
ClO 62 (2) 37 (1) 30 (1) 2 (1) 10 (1) 4 (1) 
C11 50 (1) 40 (1) 40 (1) -4 (1) 15 (1) -14(1) 
C12 37 (1) 35 (1) 36 (1) -6 (1) 1 (1) -6 (1) 
C13 26 (1) 20 (1) 28 (1) -2 (1) 2 (1) 3 (1) 
C14 34 (1) 30 (1) 28 (1) -2 (1) 2 (1) 3 (1) 
C15 39 (1) 30 (1) 31 (1) 7 (1) 4 (1) 4 (1) 
C16 32 (1) 26 (1) 41 (1) 2 (1) 11 (1) -1 (1) 
C17 32 (1) 31 (1) 29 (1) -1 (1) 0 (1) -5 (1) 
C18 33 (1) 26 (1) 28 (1) 3 (1) -2 (1) 0 (1) 
C19 34 (1) 26 (1) 28 (1) 2 (1) -4 (1) 0 (1) 
C20 30 (1) 26 (1) 23 (1) 3 (1) -6 (1) 2 (1) 
C21 31 (1) 48 (1) 27 (1) -6 (1) -6 (1) 0 (1) 
C22 35 (1) 67 (1) 38 (1) 9 (1) -5 (1) -18 (1) 
C23 59 (1) 39 (1) 41 (1) 5 (1) -23 (1) -21 (1) 
C24 51 (1) 33 (1) 34 (1) -3 (1) -16 (1) 0 (1) 
C25 34 (1) 33 (1) 27 (1) -1 (1) -6 (1) 2 (1) 
C26 32 (1) 22 (1) 33 (1) 2 (1) -3 (1) -4 (1) 
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C27 29 (1) 24 (1) 32 (1) 2 (1) 3 (1) -3 (1) 
C28 31 (1) 28 (1) 41 (1) -1 (1) -9 (1) -4 (1) 
C29 32 (1) 43 (1) 71 (1) -6 (1) 2 (1) -3 (1) 
C30 44 (1) 31 (1) 44 (1) -4 (1) -9 (1) -8 (1) 
C31 "1 (1) 44 (1) 44 (1) 8 (1) -16 (1) -12(1) 
Table 5. Hydrogen coordinates ( x 104 ) and isotropic displacement parameters ( A2 x 
103 ) 
X y z U (eq) 
H2 -407 (2) -1566 (1) 4126 (2) 29 
H8 -957 (2) -792 (1) 5808 (2) 39 
H9 -1331 (2) -1160 (1) 7604 (2) 48 
H10 -3404 (3) -1632 (1) 8048 (2) 52 
Hll -5114 (2) -1712 (1) 6734 (2) 43 
H12 -4788 (2) -1318 (1) 4962 (2) 43 
H14 -1104 (2) -2304 (1) 5439 (2) 36 
H15 -2227 (2) -3214 (1) 5912 (2) 40 
H16 -3664 (2) -3693 (1) 4644 (2) 39 
H17 -4089 (2) -3232 (1) 2930 (2) 40 
H18 -2985 (2) -2316 (1) 2463 (2) 35 
H19B -3265 (2) -373 (1) 1673 (2) 35 
H19A -2345 (2) -595 (1) 678 (2) 35 
H21 -5063 (2) -1052 (1) 2398 (2) 43 
H22 -6441 (2) -1924 (1) 2149 (2) 56 
H23 -5824 (2) -2674 (1) 872 (2) 56 
H24 -3881 (2) -2547 (1) -215 (2) 47 
H2 -2522 (2) -1677 (1) 20 (2) 37 
H26A -408 (2) -66 (1) 1575 (2) 35 
H26B -1334 (2) 121 (1) 2590 (2) 35 
H29A 4239 (2) 411 (7) 3787 (8) 73 
H29B 3436 (10) 484 (7) 2659 (6) 73 
H29C 3414 (10) -152 (1) 3297 (13) 73 
H30A 2864 (9) 1345 (1) 4543 (11) 60 
H30B 1251 (8) 1313 (1) 4495 (12) 60 
H30C 2104 (16) 1382 (1) 3390 (2) 60 
H31A 2704 (13) 373 (6) 5651 (5) 74 
H31B 2198 (18) -243 (2) 5086 (3) 74 
H31C 1127 (7) 265 (7) 5444 (7) 74 
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